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Summary of the work incorporated in the thesis with the title “PHYSICO 
CHEMICAL STUDIES OF SOME NEW HETEROCYCLIC COMPOUNDS” has 
been described as under. 
 
 The present work is divided into three parts. 
 
PART-1   SYNTHESIS AND CHARACTERIZATION 
 
 Chapter-1  Synthesis of Quinoline Derivatives 
  Section-I Synthesis of Chalcones 
  Section-II Synthesis of Schiff bases 
  Section-III Synthesis of Pyrazolyl Pyrazolines 
  Section-IV Synthesis of Thiopyrimidine 
 
 Chapter-2  Synthesis of Pyrazoles Derivatives 
  Section-I Synthesis of Imidazolinones 
 
 Chapter-3 Comparison of different methods used for synthesis 
 
 
PART-2  PHYSICO-CHEMICAL PROPERTIES  
 
 Chapter-1 Acoustical Properties 
 Chapter-2 Density and Refractive index 
 Chapter-3 Conductance 
 Chapter-4 Heat of Solutions 
 Chapter-5 Thermal Properties 
 Chapter-6 Dissociation Constants 
 






SYNTHESIS AND CHARACTERIZATION 
 
 The chemistry of the heterocyclic compounds is as logical as that of 
aliphatic or aromatic compounds. The variety of heterocyclic compounds is 
enormous, their chemistry is complex and synthesizing them requires great skill. 
  This class of compounds has great applicability as drugs due to their 
specific chemical reactivity. Further, many natural products contain heterocyclic 
compounds such as alkaloids and glycosides.  
  Taking in view of the applicability of heterocyclic compounds, the present 
work was undertaken to synthesize some new heterocycles bearing quinoline 
and pyrazole nucleus.  All the synthesized compounds were characterized by IR, 
NMR and mass spectra. 
 
Chapter-1 Synthesis of Quinoline Derivatives 
 
 Nitrogen containing heterocyclic compounds like quinoline has received 
considerable attention in recent years due to their biological and pharmaceutical 
activities. Quinoline contains a phenyl ring fused to a pyridine ring. Quinoline is 
also known as benzpyridine. 
 The chemistry of quinoline derivatives have been of interest due to its 
useful application in medicine, agriculture and industry 
  Thus the important role displayed by quinoline and its derivatives for 
various therapeutic and biological activities prompted us to synthesize of some 
schiff bases, chalcones, pyrazolines and thiopyrimidines derivatives which are 




















































Chapter-2  Synthesis of Pyrazoles Derivatives 
One of the most useful class in heterocyclic compounds is Pyrazole. The 
pyrazole ring consists of a doubly unsaturated five membered ring containing two 
adjacent nitrogen atoms. 
 The research on the chemistry of pyrazoles has been a focus of attention 
for chemists for a long time, due to their wide spread diversified biological 
activities like antitubercular, antimicrobial, hypnotics, anti-inflammatory, 







 From this pyrazole moiety various imidazolinones have been synthesized 
as mentioned in following section. 
 












Chapter-3 Comparison of different synthesis methods 
In the last few years Microwave-induced Organic Reaction Enhancement 
(MORE) chemistry has gained popularity as a non-conventional technique for 
rapid organic synthesis.  Many researchers have reported the synthetic utility of 
MORE chemistry in routine organic synthesis. Compared to traditional processing 
of organic synthesis, microwave-enhanced chemistry saves significant time and 
very often improves conversions, clean product formation.  
Ultrasound waves are known for their wide applications in various fields 
like life sciences, medical, cleaning, sonar, electronics, agriculture, 
oceanography, material science etc. Further, these waves prove to be important 
in synthetic organic chemistry by lowering the reaction temperature and reaction 
time. By using these waves, yield can be increased and one can avoid the use of 
phase transfer catalysts in chemical reactions. 
This prompted us to synthesize various Schiff bases using the Microwave-
assisted (MW) method, Ultrasound irradiation (US) and Conventional thermal 

























Chapter-1 Acoustical Properties 
 
In  this chapter, sound velocity studies of some imidazolinone derivatives 
of pyrazole aldehyde  in dimethylformamide (DMF) and dimethylsulfoxide 
(DMSO)  solution were done at 308.15 K with a view to understand the molecular 
interactions in these solutions. From these experimental data, various acoustical 
parameters such as isentropic compressibility, Rao’s molar sound function, 
specific acoustical impedance, internal pressure, Vander Waals constant, free 
volume etc. were evaluated and results are discussed. 
 
Chapter-2 Density and Refractive index 
 
Refractive index is a property of the material and is extremely useful in chemical 
analysis. In this chapter, the refractive index of imidazolinone derivatives of 
pyrazole aldehyde were measured in dimethylformamide (DMF) and 
dimethylsulfoxide (DMSO) solutions at 308.15 K. From the refractive index 





The solutions of different concentrations were prepared for each 
imidazolinone derivatives in DMF and DMSO and the conductance of each 
solution was measured and equivalent conductance at infinite dilution for different 




 Chapter-4 Heat of Solutions 
The molar heat of solution and melting temperature of a substance can be 
determined from the solubility measurement at different temperatures. In the 
present chapter,   heat   of   solution   for  all  the   imidazolinone   derivatives  
was determined at different temperatures (308.15-328.15 K) in 
dimethylformamide (DMF) and dimethylsulfoxide (DMSO). 
 
Chapter-5 Thermal Properties 
  This chapter describes the thermal properties of imidazolinone 
derivatives. The Thermo Gravimetric Analysis (TGA) measurements were made. 
From these measurements, various kinetic parameters were evaluated. Further, 
thermal stability of various compounds were also determined. 
 
Chapter-6 Dissociation Constants 
In the present Chapter, the dissociation constant of some Schiff bases 







 In the present chapter, antibacterial activity of all the pyrazole and 
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 The chemistry of the heterocyclic compounds is as logical as that of 
aliphatic or aromatic compounds. The variety of heterocyclic compounds is 
enormous, their chemistry is complex and synthesizing them requires great skill. 
 A heterocyclic compound is one which possesses acyclic structure with at 
least two different kinds of atoms in the ring. Among large number of 
heterocycles found in nature, nitrogen heterocycles are the most abundant than 
those containing oxygen or sulfur. The number of atoms in the heterocyclic ring 
can range from three to many i.e. ethylene oxide to crown ethers. Heterocyclic 
compounds can contain more than one ring system either heterocyclic or 
homocyclic. 
 Heterocyclic systems are encountered in many groups of organic 
compounds possessing great applicability in industry as well as in our life in 
various ways. Most of the sugars and their derivatives contain hetero atoms. 
Many members of the vitamin B group possess heterocyclic ring containing 
nitrogen.  
 This class of compounds has great applicability as drugs due to their 
specific chemical reactivity. They resemble essential metabolism and they fit 
biological receptors and block their normal working. Many natural products 
contain heterocyclic compounds such as alkaloids and glycosides. Many 
antibiotics including penicillin, cephalosporin, norfloxacin, streptomycin etc. also 
contain heterocyclic ring. 
 Taking in view of the applicability of heterocyclic compounds, the present 
work was undertaken to synthesize some new heterocycles bearing quinoline 




























 Nitrogen containing heterocyclic compounds like quinoline has received 
considerable attention in recent years due to their biological and pharmaceutical 
activities. Quinoline contains a phenyl ring fused to a pyridine ring. The 











 Quinoline is also known as benzpyridine. 
 Different methods used for the synthesis of quinoline and its derivatives 
have been reported in literature(1-5).   
 These quinoline derivatives are known to have wide spectrum of 
therapeutic activities such as: analgesic(6,7), antiulcer(8), bactericidal(9-11), 
antiinflammatory(12,13), antidepressant(14), Herbicidal(15,16), anticonvulsant(17), 
antitumor(18,19), antidiabetic(20), antiplatlet(21-23), antiviral(24,25), antithyroid(26), 
antiarterioscierotics(27), antihypertensive(28),  antithrombotic(29), antiallergic(30,31), 
antimalarial(32) etc. 
 Boeger et al.(33) reported pesticidal properties of some new quinoline 
derivatives. Synthesis and biological activity of 4-(3-aryl-2-oxo and 2-thioxo-1,3-
oxazolidin-5-yl-methoxy) quinoline-2-carboxylic acids was documented by Lee 
and co-workers(34). The antibacterial activity of some new quinoline derivatives 
have been reported by Fujita et al(35). Beard and co-workers(36) have prepared 
some new N-aryl substituted tetrahydroquinolines having retinoid agonist and 
retinoid antagonist type biological activity.  The anti-inflammatory activity of some 
new 5-heterocyclyquinoline was reported by Dyke and coworkers(37). Diane and 
co-workers(38) reported the anticancer activity of some new quinolines. Machhi et 
al.(39) have prepared some new aryl-quinolinyl pyrimidinones and screened for 
their antibacterial activity. Shimizu et al.(40) synthesized some new quinoline 
carboxylic acid derivatives and reported them their antibacterial activity. The 
antibacterial activity of some new fluoroquinoline derivatives(41) and  of 2-
 3
quinoline derivatives(42) have also been reported. Wackernagel(43) reported some 
new quinoline derivatives as insecticidals whereas Michaela and co-worker(44) 
have reported some other quinoline derivatives as antagonist. Some new indolo 
quinoline derivatives are known to act as antineoplastic agent(45) whereas some 
are reported to be used in the treatment of autoimmune disease and allergies(46).   
Ramharter et al.(47) reported In vitro activity of quinolines against 
Plasmodium falciparum in Gabon. Vangapandu et al.(48) reported ring-substituted 
quinolines as potential anti-tuberculosis agents. Joshi et al.(49) reported as novel 
5-substituted amino quinoline derivatives as antimalarials.  Chen et al.(50) also 
reported anticancer activity of certain quinoline derivatives. 
Recently, the anticonvulsant activity (51) and antimicrobial activity(52) of 
some new quinoline derivatives have also been reported.  Li et al.(53) studied 
antiproliferative activity of some of these derivatives.  
The anti-HIV(54), anticonvulsant(55) and anti-tuberculosis activity(56) of 
substituted quinolines have also been documented. Warshakoon et al.(57) studied 
anti-obesity properties of these compounds.      
 Thus, the important role displayed by quinoline and its derivatives for 
various therapeutic and biological activities prompted us to synthesize some 
schiff bases, chalcones, pyrazolines and thiopyrimidines derivatives bearing 
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Chalcones are colored compounds because of the presence of the 
chromophore and auxochromes. They are known as benzalacetophenones or 
benzylidene acetophenone. Kostanecki and Tambor(1) gave the name Chalcone. 
The alternative names given to chalcones are phenyl styryl ketones, 
beanzalacetophenone, b-phenyl acrylphenone, g-oxo-a,g-diphenyl-a-propylene 
and a-phenyl-b-benzoethylene 
 The chemistry of chalcones has generated intensive scientific studies 
throughout the world, due to their biological and industrial applications. 
Chalcones are characterized by their possession of a structure in which two 
aromatic rings are linked by an aliphatic three carbon chain.  
 Different methods are available in the literature for the synthesis of 
chalcones(2-11). The most convenient method is the one, that involves the Claisen-
Schimidt condensation of equimolar quantities of an aryl methyl ketones with 
arylaldehyde in presence of alcoholic alkali(12).  
 Several condensing agents such as alkali of different strength(12,13) 
aluminium chloride(14), anhydrous boron trifluoride(15),  amino acids(16), 
hydrochloric  acid(17,18), phosphorous oxychloride(19), piperidine(20), perchloric 
acid(21) etc are used in the synthesis. 
   The chalcones have been found to be useful for the synthesis of variety of 
heterocyclic compounds such as cyanopyridone(23), pyridopyrimidines(24), amino 
pyrimidines(25), 3-cyanopyridines(26), isoxazoles(27), thiazepines(28), pyrazolines(29), 
oxirane(30), 1,4-oxazipines(31), 2-isothiazolidines(32), barbitone(33), 
oxopyrimidines(34), 1-carboxamide pyrazolines(35), 2-1H-pyrimidines(36), imine 
derivatives(37). 
 Chalcones are associated with different biological activities like 
cardiovascular(38), antispasmodic(39), anthelmintics(40,41), antiulcer(42,43), 
antiinflammatory(44-46), antiviral(47), antiallergic(48), fungicidal(49-51), 
bactericidal(52,53), insecticidal(54-56),  antitumor(57-59), antileishmanial(60),  
herbicidal(61), anticancer(62,63), antitubercular(64), anti HIV(65) etc.  
  Mudalir and Joshi(66) reported insecticidal activity of some phenoxy 
chalcones. The cardiovascular activity(67) , anti tumor activity(68) and anti 
inflammatory activity(67, 69) of some chalcones have also been reported. Ko et 
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al.(70) have prepared some new chalcones for potent inhibition of platelet 
aggregation. Ziegler et al.(71) reported some  chalcones as antiparasitic. The 
antimalarial activities of chalcones have also been reported by Xue et al.(72) and 
Dominguez et al.(73). Seo et al.(74) have synthesized chalcones derivatives and 
reported them as a-glucosidase inhibitors.  Larsen and co-worker(75) and Wu et 
al.(76) have reported anti-plasmodial activity and Boeck and et al.(77) have reported 
anti leishmanial activity of some chalcones. Analogs containing nitro, fluorine or 
bromine group respectively displayed increased selectivity against the parasites 
as compared with natural chalcone.       







































Synthesis of (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-(4-methoxy 
phenyl)prop-2-en-1-one 
 
[A] Synthesis of N-(4-fluorophenyl)acetamide: 
 
 A mixture of 4-fluoroaniline (1.11g, 0.01M) and acetic anhydride (1.02g, 
0.01M) in absolute ethanol was refluxed in water bath for 2-3 hrs. using H2SO4 as 
catalyst. The crude product was isolated and crystallized from absolute ethanol. 
 
[B] Synthesis of 2-chloro-6-fluoroquinoline-3-carbaldehyde: 
 
 N-(4-fluorophenyl)acetamide (1.53g, 0.01M) was added in mixture of 
Vilsmeir-Haack reagent (prepared by dropwise addition of 6.5ml POCl3 in ice 
cooled 2ml DMF) and refluxed for 27 hrs. The reaction mixture was poured into 
ice followed by neutralization using sodium bicarbonate. Crude product was 
isolated and crystallized from ethanol. 
 
[C] Synthesis of (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-(4- methoxy     
      phenyl)prop-2-en-1- one: 
 
 To a well stirred solution of 2-chloro-6-fluoroquinoline-3-carbaldehyde 
(2.09g, 0.01M) and p-methoxy-acetophenone (1.50g, 0.01M) in ethanol (25 ml), 
40% NaOH added till the solution basic. The reaction mixture was stirred for 48 





























































 The various physical constants such as Rf value, melting point and 
percentage of yield for all the synthesized chalcones are given in Table 1.1. 
 The characterization was done by IR, 1H NMR and mass spectra. 
 
(I) INFRA RED SPECTRA: 
 Instrument: SHIMADZU-FTIR-8400 Spectrophotometer 
 Frequency range: 4000-400cm-1 
 Sample technique: KBr disc. 
 
(II) 1H NMR SPECTRA: 
 Instrument: BRUKER Spectrometer (300 MHz and 400 MHz) 
 Internal reference: TMS 
 Solvent: CDCl3/DMSO  
 
(III) MASS SPECTRA 
 GCMS-SHIMADZU-QP2010 
  
 All these spectra along with their tables are given in Fig.1.1 to 1.3 and 
Tables 1.2 to 1.3 for (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-(4-methoxy phenyl)    
prop-2-en-1-one. The proposed fragmentation of the same compound is also 



















Table 1.1: Physical constants of chalcones. 
 
 









1. NVK-1A 4-OCH3-C6H4- C19H13ClFNO2 341 0.55 215 65 
2. NVK-1B 3-NO2-C6H4- C18H10ClFN2O3 356 0.57 209 71 
3. NVK-1C 2-OH-C6H4- C18H11ClFNO2 327 0.48 225 64 
4. NVK-1D 4-NH2-C6H4- C18H12ClFN2O 326 0.64 198 63 
5. NVK-1E 4-NO2-C6H4- C18H10ClFN2O3 356 0.48 >300 59 
6. NVK-1F 3-NH2-C6H4- C18H12ClFN2O 326 0.49 222 67 
7. NVK-1G 4-CH3-C6H4- C19H13ClFNO 325 0.55 217 62 
8. NVK-1H 4-OH-C6H4- C18H11ClFNO2 327 0.78 229 71 
9. NVK-1I 4-Cl-C6H4- C18H10Cl2FNO 345 0.81 245 61 
10. NVK-1J 4-Br-C6H4- C18H10BrClFNO 390 0.88 218 57 
 
 








Figure 1.1: IR spectra of (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-(4-methoxy   
























Table 1.2: IR spectral data of (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-(4- 
         methoxy phenyl)prop-2-en-1-one. 
 
 
Frequency in cm-1 Type Vibration mode 
Observed Reported 
C-H str. (asym.) 2923 2975-5920 
C-H str. (sym.) 2849 2880-2860 
C-H def. (asym.) 1423 1470-1435 
Alkane 
(methyl) 
C-H def.(sym.) 1347 1395-1370 
C-H str. 3076 3100-3000 
C=C 1492 1585-1480 
C-H i.p. def. 1121 1125-1090 
Aromatic 
C-H o.o.p. def. 826 860-810 
C=N str. 1600 1650-1580 quinoline 
moiety C-N str. 1306 1350-1200 
C-O-C str. (asym.) 1264 1275-1200 ether 
C-O-C str. (sym.) 1024 1075-1020 
chalcone C=O str. 1657 1750-1650 
C-F 1209 1400-1000  








































Figure 1.2: 1H NMR spectra data of (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-  











Table 1.3: 1H NMR spectral data of (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-   




































Multiplicity Inference J 
(Hz) 
1. 3.91 3H singlet Ar-OCH3 - 
2. 7.00-7.03 2H doublet Ar-H(gg’) 8.9 
3. 7.48-7.58 3H multiplet Ar-H(a)+H(b)+H(c) - 
4. 7.60-7.65 1H doublet =CH(e) 15.48
5. 8.06-8.09 2H doublet Ar-H(hh’) 8.8 
6. 8.13-8.18 1H doublet =CH(f) 15.75
7. 8.42 1H singlet Ar-H(d) - 
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 Azomethines are generally known as Schiff bases to honour Schiff, who 
synthesized such compounds(1). These are the compounds containing 
characteristic –CH=N- group. Lots of works have been done on this class 
compounds due to its multi applicability. They are well known intermediate for the 
preparation of azetidinones, thiazolidinones, aryl acetamides and many other 
derivatives. 
  Owing to their characteristic properties like, manifestations of novel 
structures, thermal stabilities, abnormal magnetic properties, relevant biological 
properties, high synthesis flexibility, varied coordinating ability and medicinal 
utility, a wide range of these compounds have been synthesized and extensively 
studied(2-19).  
 Murray(20) has prepared imines by the  reaction of aldehydes with amine 
(aromatic or aliphatic). Tabei and Saitou have reported the synthesis of some 
Schiff bases derived from benzaldehyde and substituted benzaldehydes with 
aniline(21). Some Schiff bases from 2-hydroxy benzaldehydes were also 
synthesized and the effect of sunstituent on Keto-enol equilibria was also 
reported(22). Some other Schiff bases have also been synthesized from various 
substituted benzaldehydes and their characterizations were done by using IR, 
NMR and mass spectra(23-25). More et al.(26) synthesized some Schiff bases from 
aminothiazoles. Chang and Pan reported some Schiff bases derived from amino 
phenols and aromatic aldehydes(27). A new one pot procedure for the generation 
of azomethine via chlorominium salt has been investigated by Anderson and co-
workers(28).  
Literature survey reveals that azomethines have a wide range of 
applications(29-34) such as corrosion inhibitor, intermediates in various reactions, in 
perfumery etc. Some are known to be used in many potential drugs(35) and are 
known to possess broad spectrum of biological activities such as antiviral(36), 
antifungal(37), antiparasitic(38), antibacterial(39), antiinflammatory(40) etc. 
 Smalders et al.(41) reported some new azomethine as potential antitumor 
agents. Din and Nabaweyal(42) have reported antibacterial activity of some 
azomethine derivatives. Khalafallah and Hasan have also suggested some styryl 
Schiff’s bases as potential antibacterial and antifungal agents(43). Yadav and Patil 
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have reported some azomethines which were screened for their antibacterial and 
antifungal activities(44). Chohan et al.(45) have synthesized some azomethines and 
studied their antibacterial action against some gram positive and gram negative 
bacteria. Tilak et al.(46) have synthesized some Schiff bases and screened 
against carrageenin-induced edema in albino rats. The antifungal and 
antibacterial properties of some Schiff bases have also been reported by Pandey 
et al.(47) and Castellano et al.(48). The antibacterial, antifungal, anti inflammatory 
and herbicidal activity of some azomethine derivatives have also been 
documented by Holla et al.(49,50) have documented. Selvam et al. have prepared 
Schiff bases from sulfonamide and its derivatives and studied their anti-HIV 
properties(51). Rotheist et al.(52) have reported some new azomethines as 
antiparasitic agents.  Adnan et al.(53) have also reported antibacterial and 
antifungal activities of some Schiff bases. Neslishan and Reyhan(54) have studied 
their antitumor activity whereas Varma(55) evaluated their antileishmanial activity. 
Recently, Parumal and co-workers(56) have also reported antimicrobial activity of 
some synthesized azomethine derivatives. Guo et.al.(57,58) have synthesized 
schiff bases of carboxymethyl chitosan and reported their in vitro antifungal and 
antioxident activity. The anti-inflammatory, analgesic and kinase (CDK-1, CDK-5, 
and GSK-3) inhibition activity of some azomethine derivatives have also been 
studied by Sondhi et al.(59). Patole et al.(60) have reported antimycobacterial 
activity of Schiff base conjugates of p-amino salicyclic acid containing hydroxyl-
rich side chains. Cukurovali et al.(61) have also synthesized some azomethine 
derivatives and investigated their antibacterial and antifungal activity. Anti-HIV 
activity of some other Schiff’s bases have also been reported by Sriram and co-
workers(62). 
Thus, with an effort to capitalize the biological potential of the heterocyclic 
system and to provide more interesting compounds for biological study, the 














[A] Synthesis of N-(4-fluorophenyl)acetamide: 
 
 Section-1 (A) 
 
[B] Synthesis of 2-chloro-6-fluoroquinoline-3-carbaldehyde:  
 
 Section-1 (B) 
 
[C] Synthesis of N-[(1E)-(2-chloro-6-fluoroquinolin-3-yl)methylene]-4-   
       methoxyaniline: 
 
 A mixture of 2-chloro-6-fluoroquinoline-3-carbaldehyde (2.09g, 0.01M) and 
4-methoxyaniline (1.23g, 0.01M) was taken in ethanol using 2-3 drops of gla. 
Acetic acid and the reaction mixture was refluxed for 10 hrs. The product was 






























Table 2.1: Physical constants of Schiff bases. 
 
 









1. NVK-2A 4-OCH3-C6H4- C17H12ClFN2O 314 0.53 192 62 
2. NVK-2B 4-CH3-C6H4- C17H12ClFN2 298 0.52 168 65 
3. NVK-2C 4-Cl-C6H4- C16H9Cl2FN2 319 0.47 217 55 
4. NVK-2D 2-OCH3-C6H4- C17H12ClFN2 298 0.34 205 59 
5. NVK-2E 4-NO2-C6H4- C16H9ClFN3O2 329 0.48 199 45 
6. NVK-2F C6H5- C16H10ClFN2 284 0.49 188 49 
7. NVK-2G C10H7- C20H12ClFN2 334 0.71 169 58 
8. NVK-2H 3-Cl-4-F-C6H3- C16H8Cl2F2N2 337 0.44 211 69 
9. NVK-2I 4-OH-C6H4- C16H10ClFN2O 300 0.69 225 45 
10. NVK-2J 3,4-di-Cl-C6H3- C16H8Cl3FN2 353 0.33 239 48 
 
 








Figure 2.1: IR spectra of N-[(1E)-(2-chloro-6-fluoroquinolin-3-yl) methylene]- 
























Table 2.2: IR spectral data of N-[(1E)-(2-chloro-6-fluoroquinolin-3-yl)  
       methylene]-4-methoxyaniline. 
 
 
Frequency in cm-1 Type Vibration mode 
Observed Reported 
C-H str. (asym.) 2926 2975-5920 
C-H str. (sym.) 2841 2880-2860 
C-H def. (asym.) 1447 1470-1435 
Alkane 
(methyl) 
C-H def.(sym.) 1335 1395-1370 
C-H str. 3084 3100-3000 
C=C 1497 1585-1480 
C-H i.p. def. 1115 1125-1090 
Aromatic 
C-H o.o.p. def. 827 860-810 
C=N str. 1607 1650-1580 azomethine 
C-N str. 1290 1350-1200 
C-O-C str. (asym.) 1250 1275-1200 ether 
C-O-C str. (sym.) 1030 1075-1020 
C-F 1213 1400-1000  




































Figure 2.2: 1H NMR spectra of N-[(1E)-(2-chloro-6-fluoroquinolin-3-yl)  










Table 2.3: 1H NMR spectral data of N-[(1E)-(2-chloro-6-fluoroquinolin-3-yl )  






























Multiplicity Inference J 
(Hz) 
1. 3.86 3H singlet Ar-OCH3 - 
2. 6.97-7.00 2H  doublet Ar-H(ff’) 13.06
3. 7.25 1H singlet Ar-H(d) - 
4. 7.35-7.38 2H doublet Ar-H(gg’) 12.31
5. 7.51-7.57 2H multiplet Ar-H(a)+H(b) - 
6. 8.01-8.07 1H quartet Ar-H(c) - 
7. 8.98 1H singlet -CH(e)=N - 
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 Pyrazoline is a five membered heterocyclic system with two nitrogen 
atoms at the positions 1 and 2. The biodynamic behavior(1) and industrial 
applications(2) of pyrazolines have been studied extensively.  
 Various methods have been reported for the preparation of 2-pyrazoline 
derivatives. Hashsh et al. have synthesized pyrazolines by epoxidation of 
chalcones with epoxy ketones on reaction with hydrazine hydrate and phenyl 
hydrazine(3). 2-pyrazolines can also be constructed by the cyclo condensation of 
chalcones with hydrazine hydrate(4). Dipolar cyclo addition of nitrilimines of 
dimethyl fumarate, fumaronitrile and the N-aryl maleimides yielded the 
corresponding pyrazolines(5). Godaliza and co-workers(6) have prepared fused 
pyrazolines derivatives. Few workers also reported the synthesis of 2-pyrazolines 
by one pot method(7,8). Fritz et. al.(9) have synthesized some pyrazolyl 
pyrazolines. Paul et. al.(10) and Anshu et. al.(11) have described the microwave 
assisted synthesis of 2-pyrazolines. Melleller and Angew have also reported the 
synthesis of pyrazolines with a coupling-isomerisation sequence of halorene, 
propargl alcohol and methyl hydrazine(12) whereas Patel and Desai synthesized 
some 2-pyrazoline derivatives by the condensation of α,β-unsatured ketone and 
thiosemicarbazide in the presence of basic alumina and K2CO3(13). 
From the literature survey, it was revealed that pyrazolines are better 
therapeutic agents. They are known to exhibit various biological activities such as 
antidiabetic(14), tranquilizer(15), hypoglycemic(16), diuretic(17), anticonvulsant(18,19), 
antineoplastic(20),  cardiovascular(21), herbicidal(22), antiallergic(23), anti 
inflammatory(24), bactericidal(25,26),  insecticidal(27),    antiimplantation(28), 
antitumor(29), fungicidal(30), analgesic(31), antimicrobial(32) etc.  
Richard and Megan (33) investigated pyrazoines bis phosphanate ester as 
novel anti-inflammatory and antiarthritic agents. Manna and co-worker(34) have 
reported 1- acetyl-5 -(2'-bromophenyl)- 4,5 -dihydro- 3-(2'-hydroxyphenyl)- 1H -
pyrazolines and its derivatives as potent antiinflammatory, analgesic and 
antipyratic agents. Atif and coworkers(35) have patented 3-methyl-4'-(substituted 
phenylazo)-pyrazol-5-ones as antibacterial agent. Kucukguzel et. al.(36) have 
reported antimicrobial and anticonvulsant properties of some pyrazolines. Bansal 
and coworkers(37) have synthesized 1-acetyl-5-substituted ary-3-(b-
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aminoaphthyl)-2-pyrazolines and studied their antiinflamnmatory and ulcerogenic 
activities. The cardiovascular(38) and vascularization propertiesagent(39) have also 
been reported. Matysiak and  Niewiadomy (40) have synthesized some novel 
pyrazoline derivatives which exhibited comparable or higher activity than 
itraconazole and fluconazole tested under the same experimental condition. 
Berghot et. al(41) have studied antibacterial activities of pyrazole and pyrazoline 
derivatives of diazepam. Gokhan et. al.(42) have synthesized new 1,N-substituted 
thiocarbomoyl-3-phenyl-5-thienyl-2-pyrazoline derivatives and studied their for 
antidepressant, antiogenic and mammalianmonoamine oxidase (MAO)- A & B 
inhibitory activities. Ahn et. al(43) have synthesized cyano- pyrazoline derivatives 
and documented them as dipeptidyl peptidase(DP)-IVinhibitors and antidiabitic 
agents. Carrion et. al(44) have reported pyrazoline derivatives as antiinflammatory 
agents. Jeong et. al.(45) have reported pyrazole as low-density lipoprotein (LDL) 
antioxidant activity in the TBARS assay. Jones and co-workers(46) have 
synthesized 4-substituted pyrazolines and reported them as antagonists.  
Recently, Chimenti et. al(47) have discovered anti helicobacter pyroli 
activity of some substituted diphenyl pyrazolines. The antiamoebic activity of a 
series of new 1,N-substituted pyrazoline analogues of thio semicarbazones were 
reported(48). Ucar et. al(49) have synthesized 1-N-substituted thiocarbamoyl-3-
phenyl-5-thienyl-2-pyrazolines and reported as a novel cholinesterase and 
selective monoamine oxidase B inhibitors for the treatment of Parkinson’s and 
Alzeimer’s disease. Prasad et. al.(50) have also synthesized some 1,3,5-triphenyl-
2-pyrazolines and 3-(2’’-hydroxy naphthalen-1”-yl)-1,5-diphenyl-2-pyrazolines  
derivatives of type(IX) and studied their antidepressant properties. Galil et. al(51) 
reported antiandrogenic activity of some new  substituted  aryl pyrazolines. 
Budakoh and co-workers(52) have synthesized pyrazolines possessing 
antiamoebic activity.  
These biological properties prompted me to synthesize some pyrazoline 












 [A] Synthesis of N-(4-fluorophenyl)acetamide: 
 
 Section-1 (A) 
 
[B] Synthesis of 2-chloro-6-fluoroquinoline-3-carbaldehyde: 
 
 Section -1 (B)  
 
[C] Synthesis of (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-(4-methoxy    
       phenyl)prop-2-en-1- one: 
  
Section -1 (C) 
 
[D] Synthesis of 2-chloro-6-fluoro-3-[3-(4-methoxyphenyl)-4,5-dihydro-1H-    
        pyrazol-5-yl]quinoline: 
  
 A mixture of (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-(4-methoxy        
phenyl)prop-2-en-1- one (3.41g, 0.01M) and hydrazine hydrate (0.5g, 0.01M) in 
25 ml of absolute alcohol was refluxed in water bath at temp. 80-90oC for 8 hrs. 
The reaction mixture was poured into ice. The product was isolated and 
crystallized from ethanol. 
 Similarly other substituted pyrazolines have been prepared. The physical 




















Table 3.1: Physical constants of pyrazolines. 
 
 









1. NVK-3A 4-OCH3-C6H4- C19H15ClFN3O 355 0.34 198 76 
2. NVK-3B 3-NO2-C6H4- C18H12ClFN4O2 371 0.46 165 72 
3. NVK-3C 2-OH-C6H4- C18H13ClFN3O 342 0.49 223 59 
4. NVK-3D 4-NH2-C6H4- C18H14ClFN4 341 0.32 210 65 
5. NVK-3E 4-NO2-C6H4- C18H12ClFN4O2 371 0.41 202 69 
6. NVK-3F 3-NH2-C6H4- C18H14ClFN4 341 0.43 189 64 
7. NVK-3G 4-CH3-C6H4- C19H15ClFN3 340 0.33 165 66 
8. NVK-3H 4-OH-C6H4- C18H13ClFN3O 342 0.41 215 70 
9. NVK-3I 4-Cl-C6H4- C18H12Cl2FN3 360 0.63 171 59 











Figure 3.1: IR spectra of 2-chloro-6-fluoro-3-[3-(4-methoxyphenyl)-4,5-  

























Table 3.2: IR spectral data of 2-chloro-6-fluoro-3-[3-(4-methoxyphenyl)-4,5-  
        dihydro-1H-pyrazol-5-yl]quinoline. 
 
Frequency in cm-1 Type Vibration mode 
Observed Reported 
C-H str. (asym.) 2926 2975-2850 
C-H str. (sym.) 2852 2880-2860 
C-H def. (asym.) 1421 1470-1435 
Alkane 
(methyl) 
C-H def.(sym.) 1350 1395-1370 
C-H str. 3043 3100-3000 
C=C 1516 1585-1480 
C-H i.p. def. 1031 1125-1090 
Aromatic 
C-H o.o.p. def. 827 860-810 
C=N str. 1607 1650-1580 quinoline 
moiety C-N str. 1311 1350-1200 
N-H str. 1255 1275-1200 pyrazoline 
N-N 929 1150-925 
C-F 1216 1400-1000  




































Figure 3.2: 1H NMR spectra of 2-chloro-6-fluoro-3-[3-(4-methoxyphenyl)-4,5-  









Table 3.3:1H NMR spectral data of 2-chloro-6-fluoro-3-[3-(4-methoxyphenyl)- 




































Multiplicity Inference J 
(Hz) 
1. 2.91-2.97 2H triplet Ar-H(g)+H(h) - 
2. 3.86 3H singlet Ar-OCH3 - 
3. 3.78-3.86 1H multiplet Ar-H(x) - 
4. 6.89-6.92 2H doublet Ar-H(ff’) 8.88 
5. 7.47-7.51 2H multiplet Ar-H(a)+H(b) - 
6. 7.61-7.65 2H doublet Ar-H(ee’) 14.44
7. 7.98-8.01 1H doublet Ar-H(c) 13.88
8. 8.47 1H singlet Ar-H(d) - 
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The chemistry of pyrimidines and its derivatives have been studied since 
past century due to their close pharmacological association with diverse 
pharmacological properties. Pyrimidine was first isolated by Gabriel and Colman 
in 1899. Though pyrimidine itself does not exist in nature but substituted 
pyrimidines containing pyrimidine moiety are found as a part of more complex 
system and are widely distributed. 
The first primary synthesis of thiopyrimidine derivatives from aliphatic 
fragments was carried out by Frankland and Kolbs in 1848. Since then, many 
distinct primary synthetic methods have been devised(1-6). 
By using different methods thiopyrimidine have been prepared such as: by 
the condensation of esters with N-methyl thiourea(7), by the condensation of β-
dinitriles with thiourea and guanidine(8), by the condensation of β-aldehydronitrile 
with formamidine and thiourea(9). 2-mercaptopyrimidines have been synthesized 
by Anderson(10) through condensation of thiourea and substituted β-ketoester in 
presence of sodim ethoxide. Biginnelli(11) investigated that an aromatic aldehyde 
with β-ketoester and urea or thiourea yield pyrimidine derivative. Jinjun(12) have 
prepared some new pyrimidine derivatives. 
Thiopyrimidine represent one of the most active class of compounds 
possessing a wide spectrum of biological activities, such as antiviral and 
antitumor(13), antiinflammatry and analgesic(14-16), antifilarial(17), anticancer and 
herbicidal(18-20), antileishmanial(21,22), antineoplastic(23,24), antimicrobial(25), anti 
AIDS and antitumor(26), antitubercular(27), antiviral(28), antagonists(29,30), 
antitumor(31) and herbicidal(32).  
Peesapati et al.(33) have synthesized thiopyrimidine derivatives and 
reported them as potent antimicrobial agent. Mahran and co-workers(34) have 
synthesized heterocyclic system containing thiopyrimidine nucleus as potent 
antimicrobial and antitumor agent. Saneyoshi and co-workers(35) have 
synthesized thiopyrimidine nucleosides as anticancer and antiviral agent. Daniel 
et al.(36) have synthesized some novel thiopyrimidine derivatives possessing anti 
HIV activity. 
The antitumor activity(37), antimicrobial(38) and anti-herpesvirus activities(39)   
of some thiopyrimidine derivatives have also been reported.  Shishoo et al.(40) 
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have reported thiopyrimidine derivatives as A2 receptor antagonists. The 
inhibitory activity against Human Immunodeficiency Virus (HIV) of some modified 
thiopyrimidine nucleosides have also been reported(41). The antiviral activity of 
some thiopyrimidine have been reported by Jeong et al.(42) and Kim et al.(43)  
Whereas El-Fottoh et al.(44) and Saleh et al(45) have reported their anticancer and 
other pharmacological activities. Shigeta et al.(46) have studied the antiviral 
activities of 5-alkyl-2-thiopyrimidine against herpes simplex virus (HSV), varicella-
zoster virus (VZV) and human cytomegalovirus (HCMV).   
Recently, Wili et al.(47) reported herbicidal activity and Sondhi et al(48) 
reported anti-inflammatory and analgesic activity of some thiopyrimidine 
derivatives. Hammerland et al(49) reported Structure–activity relationship of 
thiopyrimidines as mGluR5 antagonists 
Thus, the important role played by thiopyrimidine nucleus for various 





































[A] Synthesis of N-(4-fluorophenyl)acetamide: 
 
 Section-1 (A) 
 
[B] Synthesis of 2-chloro-6-fluoroquinoline-3-carbaldehyde: 
 
 Section -1 (B) 
[C] Synthesis of (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-(4- methoxy     
      phenyl)prop-2-en-1- one: 
 
 Section -1 (C) 
[D] Synthesis of 4-(2-chloro-6-fluoroquinolin-3-yl)-6-(4-methoxyphenyl)-3,4-     
      dihydropyrimidine-2(1H)-thione: 
 To a well stirred solution of (2E)-3-(2-chloro-6-fluoroquinolin-3-yl)-1-(4- 
methoxyphenyl)prop-2-en-1- one (3.41g, 0.01M) and thiourea (0.76g, 0.01M) in 
ethanol (25 ml), add alcoholic KOH solution as catalyst. The reaction mixture was 
refluxed in waterbath for 12 hrs. The reaction mixture was poured into ice. The 
























Table 4.1: Physical constants of thiopyrimidine. 
 
 









1. NVK-4A 4-OCH3-C6H4- C20H15ClFN3OS 399 0.49 169 65 
2. NVK-4B 3-NO2-C6H4- C19H12ClFN4O2S 415 0.52 175 67 
3. NVK-4C 2-OH-C6H4- C19H13ClFN3OS 386 0.43 205 62 
4. NVK-4D 4-NH2-C6H4- C19H14ClFN4OS 385 0.49 226 56 
5. NVK-4E 4-NO2-C6H4- C19H12ClFN4O2S 415 0.43 245 59 
6. NVK-4F 3-NH2-C6H4- C19H14ClFN4S 385 0.42 200 71 
7. NVK-4G 4-CH3-C6H4- C20H15ClFN3S 384 0.34 192 52 
8. NVK-4H 4-OH-C6H4- C19H13ClFN3OS 386 0.41 185 61 
9. NVK-4I 4-Cl-C6H4- C19H12Cl2FN3S 404 0.33 215 52 
10. NVK-4J 4-Br-C6H4- C19H12BrClFN3S 449 0.31 187 68 
11. NVK-4K 2-CH3-C6H4- C20H15ClFN3S 384 0.48 185 56 
 
 







Figure 4.1: IR spectra of 4-(2-chloro-6-fluoroquinolin-3-yl)-6-(4-methoxy    
























Table 4.2: IR spectra data of 4-(2-chloro-6-fluoroquinolin-3-yl)-6-(4-methoxy    
               phenyl)-3,4-dihydropyrimidine-2(1H)-thione. 
 
 
Frequency in cm-1 Type Vibration mode 
Observed Reported 
C-H str. (asym.) 2922 2975-5920 
C-H str. (sym.) 2851 2880-2860 
C-H def. (asym.) 1470 1470-1435 
Alkane 
(Methyl) 
C-H def.(sym.) 1354 1395-1370 
C-H str. 3071 3100-3000 
C=C 1508 1585-1480 
C-H i.p. def. 1111 1125-1090 
Aromatic 
C-H o.o.p. def. 826 860-810 
C=N str. 1601 1650-1580 quinoline 
moiety C-N str. 1308 1350-1200 
nitrongen N-H str. 3406 3500-3310 
C-O-C str. (asym.) 1261 1275-1200 ether 
C-O-C str. (sym.) 1024 1075-1020 
 C=S str. 1172 1200-1050 
C-F 1227 1400-1000  



































Figure 4.2: 1H NMR spectra data of 4-(2-chloro-6-fluoroquinolin-3-yl)-6-(4-    









Table 4.3: 1H NMR spectra data of 4-(2-chloro-6-fluoroquinolin-3-yl)-6-(4-    


































Multiplicity Inference J 
(Hz) 
1. 7.28 1H singlet Ar-H(f) - 
2. 3.93 3H singlet Ar-OCH3 - 
3. 7.02-7.04 2H  doublet Ar-H(hh’) 8.92 
4. 7.34-7.39 2H multiplet Ar-H(b)+H(c) - 
5. 7.64-7.68 1H doublet Ar-H(a) 15.66 
6. 7.83 1H singlet -NH - 
7. 7.98-8.02 1H doublet Ar-H(e) 15.60 
8. 8.09-8.12 2H doublet Ar-H(gg’) 8.92 
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 Pyrazoles are heterocyclic organic compounds having a doubly 
unsaturated five-member ring containing two adjacent nitrogen atoms.  
Literature survey shows that synthetic pyrazole derivatives have wide 
applicability in the field of medicine, agriculture etc (1-5). 
Knorr
(6,7)
 first synthesized a compound 1-phenyl-3-methyl-5-pyrazoline, by 
the reaction of ethyl aceto acetate with phenyl hydrazine. The name pyrazole was 
given to such compounds, because the nucleus was derived from pyrrole by 
replacement of carbon by nitrogen
(8)
. 
Few workers synthesized pyrazoles as under:  
Pechmann(9) has synthesized pyrazoles by the reaction of acetylenes and 
diazomethane. Jacobs reported the synthesis by the reaction of acetylene with 
diazomethane
(10)
. Palmey synthesized two structurally isomeric pyrazoles by the 
reaction of the substituted hydrazines with 1,3-dicarbonyl compounds
(11)
. Singh 
and Ojha(12) and Esribano et al.(13) synthesized pyrazoles by the reaction of ethyl 
aceto acetate with aryl hydrazines. Or and co workers also reported some 
pyrazole analogues(14). Some pyrazole derivatives have also been reported to be 
synthesized by the reaction of acetonitrile derivatives with (DMF-DMA)
(15)
.  
Peruml et al.(16) have synthesized pyrazoles by the reaction of hydrazones with 
Vilsmeier reagent. Touzot and coworkers have reported the synthesis by the 
cyclo condensation of mono substituted hydrazines
(17)
. Boruah et al.(18) suggested 
one pot synthesis of pyrazoles from β-formyl enamides.  
Much research has been carried out with the aim to find the therapeutic 
values of pyrazole moiety, since their discovery
 (19-24)
. These derivatives were also 





















, antimicrobial(39), neurotonsin receptor(40), immino suppressants
(41,42)
.  
Various pyrazole and its derivatives have been used in many drugs
(43-45)
. Pyrazole 
derivatives have also anti HIV
(46)
 activity. Many of them are also known to be used 
as anti proliferature agent
(47)
, protein kinase inhibitors
(48) etc.  
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Hassan reported anti diabetic and antibacterial activity of some other 
pyrazoles
(49)
. Freddy et al. reported the biological activity of 4-5-dihydro-3-phenyl-
1H-pyrazole
(50)
. Shimzo and co-workers have also synthesized some pyrazole 
derivatives and reported their herbicidal activity
(51)
. Rowley and Collins et al.(52) 
have documented pyrazole derivatives  as a good dopamine D4 receptor. Some 
pyrimidinyl pyrazole derivatives are reported to exhibits a potent cytotoxic activity 
against some tumor cell lines including multidrug resistant cell lines due to the 
overexpression of P-glycoprotein(53).  Djuric and co-workers(54) have identified a 
series of bis (trifluoromethyl)pyrazoles (BTPs) as a novel inhibitor of cytokine 
production and even inhibit IL-2 production with a 10-fold enhancement over 
cyclosporine in an ex vivo assay.  Devid et al.(55) have repored pyrazoles as 
activators of the nitrile oxide receptor and  guanglate cyclase agent. Some 
pyrazole derivatives are also known to act as potent antiinflammatory agent.(56). 
Some pyrazole derivatives are known to act as  antagonist for astrogen receptor-
α(57), as reverse transcriptase inhibitors for the treatment of HIV infection(58), as 
sodium channel blocker(59), as a neuropeptide T5 receptor antagonists 
(60), as 
CCK1 receptor antagonist(61).    Daidone(62) et al. reported that some pyrazole 
derivatives with hydrazide could inhibit fibrosis. Parmar et al.(63) have synthesized 
pyrazole derivatives and studied their antiinvasive activity.  Zhang and co-
workers(64) have documented liguly potent factor Xa inhibitors with invitro 
anticoagulant activity of pyrazoles. Dardani et al. (65) have investigated 1-phenyl-
3-toluyl-4-[ortho-1’-(N-ethyl-2’-methylpropyl amine)] phenylpyrazole as antifungal 
agent and showed that mycelial growth and conidial germination of fungi were 
blocked by the compound. Recently, Wilst et al. discovered pyrazole as potential 
glucocorticoid receptor ligand
(66)
 whereas Prasanna and co-workers also reported 
pyrazoles as COX-2 inhibitors
(67). Some pyrazole derivatives act as COX-2 
inhibitors(68) which exhibited good pharmacokinatic profile (pk), intavenous and 
subcutaneous (sc) dosing and demonstrated excellent in vivo efficacy in a 
cannine synovities model.  Various other pyrazole derivatives are reported to act 
as cytotoxic (69) and antibacterial and antifungal agents.(70). Recently, Gill and co-
workers(71) have identified pyrazole as a novel p38 MAP kinase inhibitors. 
Antimalarial activity of 4-(5-trifluoromethyl-1H-pyrazol-1-yl)-chloroquine 
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analogues has also been evaluated in vitro against a chloroquine resistant 
Plasmodium falciparum clone(72).   
Recently, few workers also reported antimicrobial activity(73) leishmanicidal 
invitro activities and cytotoxic effects(74). Cheng et al.(75) have reported pyrazole 
derivatives as canine selective COX-2 inhibitors. 
 Due to good biological activity, some pyrazole derivatives were 
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The five membered heterocyclic ring system 5-oxo-imidazoline have two 








Hoffman(1) was the first to discover 5-oxo-imidazoline by heating N’-
diacetylethylene diamine in a stream of dry hydrogen chloride. Moreover, some 
compounds were prepared by Ladenburg(2) by the fusion of two equivalents of 
sodium acetate with one equivalent of ethylene diamine dihydrochloride. The 
synthesis of imidazolinones by aminolysis of oxazolone with amine has also been 
reported(3). Takeuchi et al.(4) have synthesized imidazolinones by the reaction of 
azido substituted imides with triphenylphosphine or tributylphosphine, Cai et al.(5) 
have reported 5-imidazolinone derivatives by microwaves irradiation. Various 
other workers(6-10) have also reported synthesis of some new imidazolinone 
derivatives.   
Various imidazolinones are known to exhibit a broad spectrum of biological 
activities such as sedative and hypnotics(11), bactericidal(12,13), antiinflammatory(14-
16), antihistaminic(17), antiparkinsonian(18,19),  potent CNS depressant(20,21),    
fungicidal(22,23), insecticidal(24), antagonists(25), hypertensive(26), antiviral(27), 
antitubercular(28), antimicrobial(29), antidiabatic(30), anticancer(31), 
anticonvulsant(32), etc. 
Agrochemical activity of imidazolinones have been reported by Bascou 
and coworkers(33). Kolhe and Dhingra(34) have reported anti-AIDS, antibacterial 
and fungicidal activity of some 5-oxo-imidazolines. Shah and co workers(35) have 
prepared some newimidazolines and reported anticancer and anti-HIV activity. 
Akyoshi et al.(36) have prepared some new imidazolinone derivatives and reported 
their herbicidal activity. Lucca(37) have reported imidazolinone as excellent HIV-
protease inhibitors. Pilkington and Elizabeth(38) have described and studied 
antifungal activity of imidazolinones. Kalluraya et al.(39) have synthesized 
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imidazolinone derivatives and tested for their antibacterial, antiinflammatory and 
analagesic activities. 
Griffiths and co-workers(40) had prepared imidazolinone derivatives and 
reported as angiotensin II antagonist losartan. Sayed(41) has synthesized 
imidazolinone derivatives and screened for their antibacterial and antifungal 
activities. Sharma and De(42) have formulated 5-oxo-imidazolines possessing 
potential antimicrobial activity. Peter and Vera(43) have prepared substituted 
imidazolinones which inhibited the abnormal cell growth in human body. Awashthi 
et al.(44) have synthesized some new imidazolinone derivatives and reported their 
antimicrobial activity. Hidayat and Preston(45) have reported ALS-inhibitory activity 
of imidazolinones. Ho et al.(46) have investigated some imidazolinone derivatives 
abolished the enzymatic activity as well as the binding affinity for the cofactor 
FAD (Flavin adenine dinucleotide). Solankee(47) have synthesized some 
imidazolinone derivatives and screened for their anticancer activity.  
John and Watter(48) have also studied herbicidal activity of some 
imidazolinones. The antifungal(49), antireteroviral activity(50) and anti-HIV 
activity(51) of some other imidazolinones have also been reported.   Daisuke et 
al.(52) have documented some new imidazolones as a telomeres inhibitors and 
antitumor agents. Lauter and co-workers(53) have isolated imidazoline from 
different methods and tested for the treatment of cytokine release.  Jean et al.(54) 
have also  tested the antileishmanial activity of some imidazolones. Hamdouchi 
et al.(55) have reported their potent and broad spectrum activity. Vasiliev et al.(56) 
have synthesized imidazolinone derivatives and reported their herbicidal activity.  
Jayachandran et al.(57) have also reported imidazolinones as antimicrobial 
agents. Moreover, Alister and Kogan(58) have documented herbicidal activity of 
imidazolinone derivatives. Bronson et al.(59) have reported imidazolinone 
derivatives as antibacterial agents.  
 With a view to getting better therapeutic agent, it was contemplated to 
synthesize some imidazolinone derivatives to enhance the overall activity of 








Synthesis of N-Aryl-2-aryl-4-[1’,N-phenyl-3’-p-nitrophenyl- pyrazol-4’-yl]-
imidazolin-5-ones. 
  
[A] Synthesis of N-aminophenyl-α-methyl-p-nitrophenyl azomethine: 
 A mixture of phenylhydrazine (1.08 g, 0.01M) and p-nitrophenyl aceto 
phenone (1.65 g, 0.01M) in absolute ethanol was refluxed in water bath for 2 hrs. 
in presence of 1 ml glacial acetic acid. The crude product was isolated and 
crystallised from absolute alcohol.  
 
[B] Synthesis of 1,N-phenyl-3-p-nitrophenyl-4-formyl pyrazole: 
 N-Aminophenyl-a-methyl-p-nitrophenyl azomethine (2.53g, 0.01M) was 
added in mixture of Vilsmeir-Haack reagent (prepared by dropwise addition of 3 
ml POCl3 in ice cooled 25 ml DMF). and refluxed for 5 hrs. The reaction mixture 
was poured into ice followed by neutralization using sodium bicarbonate. Crude 
product was isolated and crystallised from ethanol. 
[C] (4Z)-4-{[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]methylene}-2-
phenyl-1,3-oxazol-5(4H)-one: 
 A mixture of 1,N-phenyl-3-p-nitrophenyl-4-formyl pyrazole (2.93g, 0.01M), 
Hippuric acid (g, 0.01M), acetic anhydride (ml, 0.03M) and sodium acetate (2.0 g, 
0.03) was heated on a waterbath for 4 hrs. Resulting mass was poured into water 
filtered and crystallized from methanol.  
[D] Synthesis of N-Aryl-2-aryl-4-[1’,N-phenyl-3’-p-nitrophenyl- pyrazol-4’-
yl]-imidazolin-5-ones. 
 To a solution of (4Z)-4-{[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl] 
methylene}-2-phenyl-1,3-oxazol-5(4H)-one (4.36g, 0.01 mol) and p-methoxy- 
aniline (1.23g, 0.01 mol) in dry pyridine (25 ml) was refluxed for 12 hrs. on oil 
bath. The content was poured on to crushed ice and neutralized with HCl, the 








































































Table 5.1: Physical constants of Imidazolinones. 
 
 









1. PAIM-1 4-CH3-C6H4- C32H23O3N5 525 0.48 215 69 
2. PAIM-2 4-OCH3-C6H4- C32H23O4N5 541 0.51 205 72 
3. PAIM-3 2-OCH3-C6H4- C32H23O3N5 525 0.42 226 65 
4. PAIM-4 C10H7- C35H25O3N5 564 0.47 232 67 
5. PAIM-5 4-F-C6H4- C31H20O3N5F 529 0.42 198 62 
6. PAIM-6 4-Cl-C6H4- C31H20O3N5Cl 546 0.43 203 65 
7. PAIM-7 C6H5- C31H21O3N5 511 0.33 189 66 
8. PAIM-8 3-Cl-4-F-C6H3- C31H19O3N5FCl 564 0.32 211 68 













Figure 5.1: IR spectra data of N-Aryl-2-akyl-4-[1’,V-phenyl-3’-p-nitrophenyl- 
























Table 5.2: IR spectral data of N-Aryl-2-akyl-4-[1’,V-phenyl-3’-p-nitrophenyl- 




Frequency in cm-1 Type Vibration mode 
Observed Reported 
C-H str. (asym.) 2956 2975-5920 
C-H str. (sym.) 2835 2880-2860 
C-H def. (asym.) 1444 1470-1435 
Alkane 
(methyl) 
C-H def.(sym.) 1340 1395-1370 
C-H str. 3129 3150-3000 
C=C 1579 1585-1480 
C-H i.p. def. 1107 1125-1090 
Aromatic 
C-H o.o.p. def. 826 860-810 
C=N str. 1598 1650-1580 Pyrazole 
moiety C-N str. 1257 1350-1200 
C-O-C str. (asym.) 1291 1275-1200 Ether 
C-O-C str. (sym.) 1035 1075-1020 





































Figure 5.2: 1H NMR spectra data of of N-Aryl-2-aryl-4-[1’,V-phenyl-3’-p- 











Table 5.3: 1H NMR spectra data of of N-aryl-2-aryl-4-[1’,V-phenyl-3’-p-    










































Multiplicity Inference J 
(Hz)
1. 3.86 3H singlet Ar-OCH3 - 
2. 6.95-6.97 2H d. doublet Ar-H(gg’) 8.88
3. 7.11-7.13 2H d. doublet Ar-H(dd’) 8.88
4. 7.28 1H singlet Ar-H(k) - 
5. 7.37-7.45 4H multiplet Ar-H(hh’)+H(ii’) - 
6. 7.47-7.58 2H multiplet Ar-H(a)+H(j) - 
7. 7.61-7.63 2H doublet Ar-H(bb’) 8.52
8. 7.89-7.91 2H doublet Ar-H(cc’) 8.72
9. 7.97-7.99 2H d. doublet Ar-H(ee’) 8.84
10. 8.39-8.41 2H d. doublet Ar-H(ff’) 8.84
11. 9.36 1H singlet Ar-H(x) - 
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Developing chemical compounds with the desired biological properties is 
time consuming and expensive. Consequently, increasing interest is being 
directed towards technologies that allow more rapid synthesis and screening of 
chemical substances to identify compounds with functional qualities. 
The research on the chemistry of schiff bases have been a focus of 
attention for chemists for several years due to their wide spread diversified 
biological activities such as antibacterial(1-3), antifungal(4-5), anti-inflammatory(6), 
analgesic(7), anticancer(8), anti-HIV(9) etc. This prompted us to synthesize various 
substituted schiff bases using the Microwave-assisted method (MW), Ultrasonic 
irradiation (US) and Conventional thermal method (Con.) 
 The microwave region of the electromagnetic spectrum lies between 1 cm 
and 1 m, most domestic and commercial microwave instruments operate at 2.45 
GHz. When a molecule is irradiated with microwaves, it rotates to align itself with 
the applied field. The frequency of molecular rotation is similar to the frequency of 
microwave radiation and consequently the molecule continually attempts to 
realign itself with the changing field and energy is absorbed. It is particularly 
convenient that qualitatively, the larger the dielectric constant the great the 
coupling with microwaves. Thus, solvents such as water, methanol, DMF, ethyl 
acetate, acetone, chloroform, acetic acid and dichloromethane are all heated 
when irradiated with microwaves. 
 In the last few years, Microwave-induced Organic Reaction Enhancement 
(MORE) chemistry has gained popularity as a non-conventional technique for 
rapid organic synthesis(10). 
 Many researchers have reported the synthetic utility of MORE chemistry in 
routine organic synthesis(11-13). Compared to traditional processing of organic 
synthesis, microwave-enhanced chemistry saves significant time and very often 
improves conversions, clean product formation etc. Further, it offers low cost with 
simplicity in processing and handling(14). This technique has been used to 
promote a variety of chemical reactions such as additions, cycloadditions, 
substitutions, eliminations, fragmentations etc(15-21).  
 Recently much has been done in microwave enhanced solvent-free 
organic synthesis(22-34). 
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 Further, ultrasonic waves have been used for organic synthesis(35-37). 
These ultrasonic waves have frequencies greater than 20,000 cycles/sec. The 
ultrasound waves are known for their wide applications in various fields like life 
sciences, medical, cleaning, sonar, electronics, agriculture, oceanography, 
material science etc
(38-42)
. Literature survey shows that few workers synthesized 
some compounds using ultrasonic technique(43-54), at lower reaction temperature 
and in less reaction time(55). 
 Therefore in the present chapter, some schiff bases have been 
synthesized by conventional method, microwave technique and by using 
ultrasound waves. 
 The reaction scheme for the synthesis is already given in Section-I of 























RESULTS AND DISCUSSIONS  
 
 The reaction time and yield of different synthesized compounds by using 
microwave, ultrasonic waves and conventional techniques are reported in Table 
1. It is observed that using microwave and ultrasonic waves, the reaction time is 
reduced considerably whereas % yield increased markedly.  
        Further, the amount of catalyst required in these techniques is very less in 
comparison to conventional method. 



























Table 1: Comparison of %yield and reaction time of compounds    
               synthesized by Microwave-induced method (MW), Ultrasonic    
               irradiation (US) and Conventional thermal method (Con.) methods.  
 
Yield % Reaction time 
Code 







NVK-2A 74 67 62 10 2.00 12 
NVK-2B 71 68 65 8 2.00 12 
NVK-2C 69 62 55 9 2.15 11 
NVK-2D 68 66 59 10 2.10 11 
NVK-2E 71 62 45 10 2.00 12 
NVK-2F 72 64 49 8 2.00 12 
NVK-2G 68 65 58 8 2.00 12 
NVK-2H 76 71 69 7 2.15 12 
NVK-2I 66 59 45 9 2.30 12 
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Much advancement has been made in the field of science and technology 
which helped people in leading a sophisticated yet luxurious life. 
Several physico chemical parameters are available in the list and few of 
them are of much interest. It was well understood by the literature that physico 
chemical properties such as acoustical properties, conductivity, density, refractive 
index, dissociation constant etc. have contributed advancement in the physical 
sciences and also in daily human life. Drug macro-molecular interactions are an 
important phenomenon in physiological media, such as blood, membranes and 
intra and extra cellular fluids. Thermodynamic properties like partial molar volume 
and partial molar compressibility are the few sensitive indicators for 
understanding molecular interactions. 
Refractive index is a very useful method to determine the structure and 
identity of unknown compounds. Thermal analysis is one the important tool for 
the study of thermal transformation of materials. 
The study of physicochemical properties of compounds in solutions gives 
complete understanding of the behavior of compounds in different solvents. 
Literature survey shows that very little work has been reported for the study of 
physico chemical studies such as thermal properties, refractive index, 
conductance and ultrasonic of the heterocyclic compounds.    
Thus, in this part of the thesis we have tried to add something in this field 
of science. Various physicochemical properties such as refractive index, heat of 
solution, conductance, thermal properties and acoustical properties for 
imidazolinone derivatives were determined in different solvents whereas 





























 Ultrasonic deals with study and application of high frequency sound waves 
usually in excess of 20 KHz (20,000 cycles per second). It works on the basis of 
piezoelectric effect(1-3).   
 Ultrasonic waves have wide range of applications in various fields(4-8) such 
as medicine, industry, material testing, under water ranging (depth gauges, 
SONAR) and cleaning (ultrasonic bath). 
  In medicine, it is used for various diagnosis such as pediatrics(9), vascular 
diseases(10), brain diseases(11), ophthalmology(12), in urology(13), in cancer cell(14) 
etc. It is also used to detect tumor of oral cavity(15), follow-up of wilm’s tumor in 
the mouse(16), urethral obstruction and diverticulum of the urinary bladder(17). 
Ultrasound therapy is also used in postmortem diagnosis(18). Further, it is useful 
to obtain the information about bone microstructure(19), lung microstructure(20) and 
biological structures(21).  
 Ultrasonic technology is employed in food(22) and dairy industry(23). It is 
also useful for investigation of wheat starch restrogadation(24), in noncontact 
method to monitor the doneness of bakery products(25) and for food drying 
process(26). It is also applied for inactivation of micro-organisms in milk and apple 
cider(27), for hydrogen peroxide bleaching of cotton(28). 
         For the polishing of mold steel(29) and extraction of various compounds(30-33) 
also, ultrasonic waves have been used. These waves have also been used in 
animal communication (e.g. bat navigation and dog whistles).  
 Now a days, lots of interest has been generated on the use of ultrasound 
radiation in synthetic organic chemistry, which includes decrease of reaction time, 
increase of yield, lower reaction temperature, avoidance of phase transfer 
catalysis etc(34-39). 
 In addition to these, ultrasonic waves provide valuable information about 
the structure of solids(40-41). By ultrasonic velocity measurements, the molecular 
interactions in pure liquid(42-45), aqueous solutions(46-48) and liquid mixtures(49-52) 
have also been studied. It provides a powerful, effective and reliable tool to 
investigate properties of solutions of polymers(53-64), carbohydrates(65-71),  amino 
acid(72-77)  etc. However, little work has been done for solid organic compounds 
solutions(78-82).  
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 Thus, in the present chapter, sound velocity studies of some imidazolinone 
derivatives in dimethylformamide (DMF) and Dimethylsulphoxide  (DMSO) 
solutions were done at 308.15K with a view to understand the molecular 
interactions in these solutions. 
 






























Choice of Solvents: 
 N,N-Dimethylformamide (DMF) and dimethylsulphoxide (DMSO) and have 
been chosen as solvents in the present work. These two solvents are of industrial 
interest because of their wide use as solvents and solubilizing agents. 
 The densities, viscosities and ultrasonic velocities of solvents and 
solutions of different concentration were measured at 308.15 K by using 
pyknometer, an Ubbelohde suspended level viscometer and single frequency 
ultrasonic interferometer operating at 2 MHz, with the uncertainties of 0.0001 
g/cm3, + 0.06 % and 0.01% respectively. 
Density measurements: 
              The weight of distilled water, pure solvents and solutions of 
imidazolinone derivatives were measured by using pyknometer. The densities 
were evaluated by using following equation: 
( ) ( )( )( )3 wt. of solvent or solution density of waterρ g cm = wt. of water        … (1.1) 
Viscosity Measurements: 
           To determine the viscosity of solution, Ubbelohde viscometer
(83)
 was used, 
which obeys Stoke’s low
(84)
. The measured quantity of the distilled water / solvent 
/ solution was placed in the viscometer, which was suspended in a thermostat at 
308.15 K. The digital stopwatch, with an accuracy of + 0.01 sec was used to 
determine flow time of solutions. Using the flow times (t) and known viscosity of 
standard water sample, the viscosity of solvent and solutions were determined 
according to equation: 





η ρ=                                                        ... (1.2) 
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Sound velocity measurement: 
                 Ultrasonic interferometer (Model No. F-81), Mittal Enterprise, New 
Delhi, working at frequency (F) of 2 MHz was used to determine sound velocity. 
                  The solvent / solution were filled in the measuring cell with quartz 
crystal and then micrometer was fixed. The circulation of water from the 
thermostat at 308.15 K was started and test solvent / solution in the cell is 
allowed to thermally equilibrate. The micrometer was rotated very slowly so as to 
obtain a maximum or minimum of anode current (n). A number of maximum 
reading of anode current were counted. The total distance (d) travel by the 
micrometer for n=10, was read. The wave length (λ) was determined according to 
the equation (1.3). 
                                         2d
n
λ =          … (1.3) 
               The sound velocity (U) of solvent and solutions were calculated from the 
wavelength and frequency (F) according to equation (1.4). 
                                                U Fλ=      ... (1.4) 
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RESULTS AND DISCUSSION  
          
The density (ρ), viscosity (η) and sound velocity (U) of pure solvents and 
different imidazolinone derivatives solutions in N,N-dimethylformamide (DMF) 
and dimethylsulphoxide (DMSO) were calculated at 308.15  K and are given in 
Table 1.1. 
         From these measurements, various acoustical parameters like specific 
acoustical impendence (Z), isentropic compressibility (κs), intermolecular free 
length (Lf), Rao’s molar sound function (Rm), molar compressibility (W), Vander 
Waals constant (b), relaxation strength (r), internal pressure (π ), solvation 
number (Sn) etc., were evaluated using the following equations: 
1.  Specific acoustical impedance: 
          Specific acoustical impedance (Z) can be calculated as: 
    Z Uρ=      ... (1.5) 
2.  Isentropic compressibility: 




    2
1
s U
κ ρ=      … (1.6) 
3.  Intermolecular free path length: 
 Jacobson
(86)
 proposed an equation to calculate the intermolecular free 
path length (Lf), which is given below: 
    1 2f j sL K κ=        … (1.7) 
where KJ is Jacobson constant (=2.0965 X 10
-6)   
4.  Molar compressibility: 
          Molar compressibility (W) can be calculated by the following equation
(87)
: 
    1 7s
MW κρ
− =   
    … (1.8) 
The apparent molecular weight (M) of the solution can be calculated according to 
equation (1.9): 
    1 1 2 2M MW M W= +     … (1.9) 
where W1 and W2 are weight fractions of solvent and solute, respectively. M1 
and M2 are the molecular weights of the solvent and compounds respectively.  
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5.  Rao’s molar sound function: 
          Rao’s molar sound function (Rm) can be evaluated by an equation given 
by Bagchi et al.
(88)
: 
   1 3m
MR Uρ
 =   
     … (1.10) 
6.  Van der Waals Constant: 








    = − + −         
    ... (1.11) 
where R is the gas constant (=8.3143 JK-1 mol-1) and T is the absolute 
temperature. 
7.  Relaxation Strength: 
          The relaxation strength (r) can be calculated as follows
(90)
:  




 = −   
      … (1.12) 
where U∞ = 1.6 x 105 cm/sec.  
8. Relative Association (RA): 









 =   
     …  (1.13) 
where U, 0U  and ρ , 0ρ  are ultrasonic velocities and densities of solution and 
solvent respectively. 
9.  Internal Pressure: 
          Suryanarayana and Kuppuswamy
(91) gave the following equation for 
evaluating internal pressure:  
   





η ρπ  =   
    … (1.14) 
where b is the packing factor (= 2). K is a constant (=4.28 X 109).  The internal 
pressure (π ) depends on temperature, density, ultrasonic velocity and specific 
heat at constant pressure. 
10.    Free Volume: 
   Free volume
(92)
 can be calculated according to equation (1.15): 
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 =   
     …  (1.15) 
The apparent molar compressibility ( Kφ ) of the solutions was calculated by 
the following equation: 
 






ρ κ ρκ κφ ρ ρ
−= +      … (1.16) 
where ρ0 and 0sκ  are density and isentropic compressibility of pure solvent 
respectively, c is the concentration of the solution and M2 is the molecular weight 
of the compound.  
 Some of these calculated parameters are given in Tables 1.2 and 1.3. 
 Fig. 1.1 and 1.2 shows the variation of ultrasound velocity (U) with 
concentrations for all the imidazolinone derivatives in both solvents, DMF and 
DMSO. It is observed that ultrasonic velocity (U) increases with concentration for 
all the compounds. The velocity depends on intermolecular free length (Lf). The 
velocity increases with decreases in Lf or vice versa. Tables 1.2 and 1.3 shows 
that Lf decreases continuously which suggest that there is strong interaction 
between solvent (both DMF and DMSO) and compound molecules. 
This is further supported by isentropic compressibility (κs) and relaxation 
strength (r). The variation of isentropic compressibility (κs) with concentration of 
these compounds are also shown in Fig. 1.3 and 1.4 for both solvents. It is 
observed from Fig. 1.3 and 1.4 and Tables 1.2 and 1.3 that both isentropic 
compressibility (κs) and relaxation strength (r) are also observed to decrease with 
concentration for all the compounds.  The decrease of κs with increasing 
concentration might be due to aggregation of solvent molecules around solute 
molecules indicating thereby the presence of solute-solvent interactions. The 
increase of acoustical impedance (Z) (Tables 1.2 and 1.3) further confirms the 
solute-solvent interactions in these systems. 
The correlation coefficient (γ) and correlation equations for some of the 
parameters are given in Table 1.4. It is observed that properties like Rao’s molar 
sound function (Rm), molar compressibility (W) and Vander Waal’s constant (b) 
are observed to increase linearly with concentration for all the compounds. The 
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linear variation of these acoustical properties indicates absence of complex 
formation. 
The internal pressure (π) is the results of forces of attraction and repulsion 
between the molecules in solutions. Tables 1.2 and 1.3 shows that internal 
pressure decreases with concentration, which indicates the decrease in cohesive 
forces. Although decrease in compressibility (κs), intermolecular free length (Lf), 
relaxation strength (r) and increase of velocity (U), viscosity (η) suggest 
predominance of solute-solvent interactions, the decrease in internal pressure 
indicates the existence of solute-solute interactions also in these systems. 
The free volume (Vf) of solute molecule at particular temperature and 
pressure depends on the internal pressure of liquid, in which it was dissolved. 
The decrease in molecular association causes an increase in free volume (Vf). 
Thus, free volume is an inverse function of internal pressure. It is evident from 
Table 1.2 and 1.3 that Vf increases with concentration for all the compounds in 
solutions. Hence, increase in free volume causes internal pressure to decreases, 
which indicates the solute-solute interactions. This suggests that both solute-
solute and solute-solvent interactions exist in these systems. 
Further, the apparent molar compressibilities (φk) of the solutions is fitted 
to Gucker’s relation (93). 
φk = φok + Sk √C 
From the plot of φk verses √C, φok and Sk values are evaluated from the 
intercept and slope. The isentropic compressibility of all the solutions were also 
fitted to the following Bachem’s relation(94): 
0 3 2
s s AC BCκ κ= + +  
and values of A and B were evaluated from the intercept and slope respectively. 
0
sκ  is the isentropic compressibility of pure solvent. All these values of intercept 
and slopes are given in Table 1.5 for DMF and DMSO. 
 Table 1.5 shows that in DMF, A and φok values are negative whereas B 
and Sk values are positive. In DMSO also (Table 1.5) A values are negative. 
However, φok values are negative for some cases and positive for others. φok 
values are negative except for PAIM-1, PAIM-2, PAIM-8 and PAIM-9, which have 
low positive values. B and Sk values are also positive. The negative A and φok 
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values and positive B and Sk values suggest predominance of solute-solvent 
interactions. 
The interactions occurring in different solutions can also be confirmed by 
the solvation number (Sn), which is measure of structure forming or structure 
breaking tendency of solute in a solution. Fig. 1.5 and 1.6 shows the variation of 
solvation number (Sn) with concentrations for all the compounds in the both 
solvents. For PAIM-2 and PAIM-6, Sn values are found increase with 
concentration in DMF. The increases in solvation number suggest increase in 
structure forming tendency of compound in a solution. However, for other 
compounds (except PAIM-4) at low concentration (0.01M), Sn values are higher 
but as concentration is increased it dropped suddenly and then it increases 
further with concentration. In some cases, after increasing, it becomes almost 
constant. This suggests that structure forming tendency decreases with 
concentration in most of the compounds, which may be due to dipole-dipole 
interactions, steric hindrance. Such interactions may cause weakening between 
solute and solvent molecules. This weak association is further confirmed by low 
relative association value (RA), which is almost same for some compounds (Table 
1.2). 
 In PAIM-4 solutions, Sn values decreases with concentration 
suggesting thereby structure breaking tendency of this compound in DMF. The 
structure forming or structure breaking tendency depends on the type of solvent 
and types of substituent group in the compound. PAIM-4 contains bulky             α-
napthylamine group, which may be the reason for structure breaking tendency of 
PAIM-4 in DMF.   
 In DMSO (Fig. 1.5 and 1.6), for PAIM-5 and PAIM-6 Sn values increase 
with concentration. However, for other compounds at low concentration (0.00M) 
Sn values are higher at the beginning (except PAIM-8) but as concentration is 
increased, it dropped suddenly and then it increases again with concentration. 
Whereas in others, after increasing it becomes almost constant. In PAIM-8 
solutions, Sn values decreases continuously with concentration suggesting 
thereby structure breaking tendency of this compound. Thus, structure forming 
tendency decreases with concentration in most of the compounds indicating 
thereby weak interactions. This weak association is further confirmed by low 
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relative association value (RA), which is almost same for some compounds (Table 
1.2).   
 Thus, it is concluded that in both DMF and DMSO solutions of studied 
compounds, both solute-solute and solute-solvent interactions exist.  
 
 






































Figure 1.1: Variation of ultrasonic velocity (U) with concentration in [A] DMF  

















































Figure 1.2: Variation of ultrasonic velocity (U) with concentration in [A] DMF  

















































Figure 1.3: Variation of Isentropic Compressibility (κs) with concentration in   




















































Figure 1.4: Variation of Isentropic Compressibility (κs) with concentration in  




















































Figure 1.5: Variation of Solvation number (Sn) with concentration in [A] DMF  
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Figure 1.6: Variation of Solvation number (Sn) with concentration in [A] DMF  
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Table 1.1: The density (ρ), ultrasonic velocity (U) and viscosity (η) of Imidazolinone derivatives in DMF and DMSO   




























 DMF DMSO 
 PAIM -1 PAIM -1 
0.00 0.9249 1.4136 7.1536 1.0546 1.4660 10.6786 
0.01 0.9268 1.4168 7.3048 1.0548 1.4692 10.8684 
0.02 0.9285 1.4228 7.5165 1.0556 1.4748 11.0201 
0.04 0.9301 1.4300 7.7198 1.0569 1.4796 11.2149 
0.06 0.9328 1.4364 7.8222 1.0578 1.4868 11.3297 
0.08 0.9357 1.4512 7.9827 1.0585 1.4948 11.5119 
0.10 0.9393 1.4604 8.1928 1.0593 1.5036 11.6860 
 PAIM -2 PAIM -2 
0.01 0.9254 1.4188 7.7407 1.0548 1.4668 11.4230 
0.02 0.9266 1.4236 7.9298 1.0556 1.4696 11.4607 
0.04 0.9277 1.4292 8.4518 1.0568 1.4720 11.7311 
0.06 0.9288 1.4348 8.5310 1.0576 1.4752 11.8204 
0.08 0.9325 1.4396 8.6057 1.0587 1.4796 11.9286 
0.10 0.9357 1.4452 8.7669 1.0596 1.4844 12.0699 
 PAIM -3 PAIM -3 
0.01 0.9254 1.4164 7.3723 1.0547 1.4684 10.9877 
0.02 0.927 1.4220 7.5268 1.056 1.4756 11.1123 
0.04 0.9292 1.4268 7.6920 1.0571 1.4808 11.3051 
0.06 0.9312 1.4336 7.8630 1.0577 1.4884 11.5032 
0.08 0.9327 1.4408 8.0824 1.0585 1.4956 11.7619 
0.10 0.9338 1.4556 8.5520 1.0592 1.5008 12.1373 






























 DMF DMSO 
 PAIM -4 PAIM -4 
0.00 0.9249 1.4136 7.1536 1.0546 1.4660 10.6786 
0.01 0.9251 1.4164 7.3415 1.055 1.4700 10.8602 
0.02 0.9283 1.4184 7.5614 1.0557 1.4752 11.0263 
0.04 0.9300 1.4232 7.7144 1.0572 1.4804 11.2326 
0.06 0.9332 1.4440 7.9644 1.0584 1.4888 11.4098 
0.08 0.9342 1.4532 8.2004 1.0593 1.4988 11.5934 
0.10 0.9361 1.4644 8.2868 1.0603 1.5148 11.7999 
 PAIM -5 PAIM -5 
0.01 0.9257 1.4152 7.8240 1.0547 1.4716 10.9877 
0.02 0.9277 1.4272 8.0638 1.0554 1.4764 11.0351 
0.04 0.9313 1.4304 8.4665 1.0564 1.4844 11.2105 
0.06 0.9332 1.4388 8.7329 1.0572 1.4892 11.3814 
0.08 0.9356 1.4496 8.9900 1.0576 1.4972 11.6108 
0.10 0.9375 1.4604 9.0803 1.0585 1.5056 11.8030 
 PAIM -6 PAIM -6 
0.01 0.9257 1.4240 7.4549 1.0548 1.4716 11.0262 
0.02 0.9284 1.4324 7.5652 1.0556 1.4780 11.1080 
0.04 0.9307 1.4448 7.8753 1.0569 1.4848 11.3038 
0.06 0.9335 1.4564 8.0176 1.0582 1.4916 11.5746 
0.08 0.9373 1.4620 8.2337 1.0594 1.4964 11.7557 
0.10 0.9396 1.4648 8.4782 1.0601 1.5032 11.9872 































 DMF DMSO 
 PAIM -7 PAIM -7 
0.00 0.9249 1.4136 7.1536 1.0546 1.4660 10.6786 
0.01 0.9267 1.4188 7.3212 1.0549 1.4708 10.8387 
0.02 0.9287 1.4292 7.4287 1.0556 1.4736 10.9424 
0.04 0.9300 1.4368 7.5015 1.0568 1.4780 11.0514 
0.06 0.9328 1.4492 7.7482 1.0581 1.4832 11.2413 
0.08 0.9346 1.4600 7.8032 1.0592 1.4892 11.3327 
0.10 0.9382 1.4756 7.9198 1.0596 1.4992 11.4330 
 PAIM -8 PAIM -8 
0.01 0.9256 1.4176 7.7483 1.0551 1.4676 10.9261 
0.02 0.9277 1.4252 8.0676 1.0556 1.4692 11.2020 
0.04 0.9304 1.4360 8.2634 1.0567 1.4744 11.4350 
0.06 0.9330 1.4504 8.3877 1.0581 1.4796 11.5872 
0.08 0.9356 1.4608 8.5949 1.0593 1.4860 11.7623 
0.10 0.9369 1.4740 8.7661 1.0599 1.4956 11.9473 
 PAIM -9 PAIM -9 
0.01 0.9252 1.4180 7.3850 1.0555 1.4684 10.9900 
0.02 0.9274 1.4248 7.5601 1.0566 1.4732 11.2092 
0.04 0.9287 1.4340 7.8404 1.0576 1.4780 11.4516 
0.06 0.9321 1.4444 8.1096 1.0587 1.4848 11.6665 
0.08 0.9351 1.4508 8.4292 1.0596 1.4908 11.9465 
0.10 0.9364 1.4592 8.6856 1.0603 1.4980 12.0950 
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0.00 0.1542 0.2194 1.3074 4.1166 2.3144 79.0228 478.9820 0.1960 1.0000 
0.01 0.1537 0.2159 1.3131 4.2553 2.3928 81.6229 465.0723 0.2007 1.0013 
0.02 0.1529 0.2092 1.3211 4.3969 2.4726 84.2204 453.4569 0.2034 1.0017 
0.04 0.1520 0.2012 1.3300 4.6830 2.6335 89.5511 426.3500 0.2164 1.0018 
0.06 0.1511 0.1940 1.3399 4.9604 2.7901 94.7135 400.5261 0.2334 1.0032 
0.08 0.1493 0.1774 1.3579 5.2441 2.9495 99.7890 378.1764 0.2498 1.0029 
0.10 0.1481 0.1669 1.3718 5.5138 3.1020 104.7019 360.3942 0.2621 1.0046 
PAIM-2 
0.01 0.1536 0.2137 1.3130 4.2742 2.4028 81.9479 476.5570 0.1851 0.9993 
0.02 0.1530 0.2083 1.3191 4.4278 2.4892 84.7980 462.4038 0.1892 0.9995 
0.04 0.1523 0.2021 1.3259 4.7368 2.6629 90.5965 440.7996 0.1914 0.9994 
0.06 0.1516 0.1958 1.3326 5.0451 2.8361 96.3673 411.0275 0.2086 0.9992 
0.08 0.1508 0.1904 1.3424 5.3334 2.9994 101.7605 385.9981 0.2259 1.0021 
0.10 0.1500 0.1841 1.3523 5.6225 3.1630 107.1384 365.5411 0.2399 1.0042 
PAIM-3 
0.01 0.1539 0.2163 1.3107 4.2615 2.3958 81.7506 466.7857 0.1979 0.9999 
0.02 0.1531 0.2101 1.3182 4.4036 2.4759 84.3656 453.3518 0.2028 1.0003 
0.04 0.1524 0.2048 1.3258 4.6846 2.6343 89.6484 425.7257 0.2169 1.0015 
0.06 0.1515 0.1972 1.3350 4.9671 2.7934 94.9044 401.3631 0.2310 1.0021 
0.08 0.1507 0.1891 1.3438 5.2520 2.9536 100.1799 380.7734 0.2428 1.0020 
0.10 0.1490 0.1724 1.3592 5.5486 3.1194 105.4779 366.7280 0.2452 0.9998 





















0.00 0.1542 0.2194 1.3074 4.1166 2.3144 79.0228 478.9820 0.1960 1.0000 
0.01 0.1539 0.2163 1.3103 4.2864 2.4097 82.2286 462.7260 0.2008 0.9996 
0.02 0.1534 0.2141 1.3167 4.4400 2.4971 85.1348 449.8610 0.2039 1.0025 
0.04 0.1528 0.2088 1.3236 4.7693 2.6826 91.3455 417.4669 0.2216 1.0032 
0.06 0.1503 0.1855 1.3475 5.1060 2.8714 97.3230 390.4225 0.2386 1.0018 
0.08 0.1493 0.1751 1.3576 5.4426 3.0603 103.5193 367.2750 0.2534 1.0008 
0.10 0.1480 0.1623 1.3708 5.7746 3.2467 109.5532 343.9172 0.2755 1.0003 
PAIM-5 
0.01 0.1540 0.2177 1.3101 4.2619 2.3963 81.7805 480.7939 0.1810 1.0005 
0.02 0.1525 0.2043 1.3240 4.4114 2.4801 84.4119 467.9142 0.1843 0.9998 
0.04 0.1519 0.2008 1.3321 4.6885 2.6371 89.6480 445.5827 0.1892 1.0030 
0.06 0.1508 0.1913 1.3427 4.9784 2.8001 95.0042 421.2496 0.1994 1.0030 
0.08 0.1495 0.1792 1.3562 5.2664 2.9622 100.2507 399.4138 0.2101 1.0031 
0.10 0.1483 0.1669 1.3691 5.5566 3.1252 105.5132 376.3731 0.2266 1.0027 
PAIM-6 
0.01 0.1530 0.2079 1.3182 4.2805 2.4060 81.9678 466.6143 0.1971 0.9984 
0.02 0.1519 0.1985 1.3298 4.4327 2.4919 84.7163 450.3275 0.2052 0.9994 
0.04 0.1504 0.1846 1.3447 4.7465 2.6682 90.4540 423.2915 0.2168 0.9990 
0.06 0.1490 0.1714 1.3595 5.0548 2.8416 96.0731 395.9151 0.2348 0.9993 
0.08 0.1481 0.1651 1.3703 5.3466 3.0069 101.4900 374.8622 0.2479 1.0021 
0.10 0.1477 0.1619 1.3763 5.6423 3.1739 107.0335 356.7227 0.2587 1.0039 






















0.00 0.1542 0.2194 1.3074 4.1166 2.3144 79.0228 478.9820 0.1960 1.0000 
0.01 0.1535 0.2137 1.3148 4.2501 2.3897 81.4861 466.2041 0.1999 1.0007 
0.02 0.1522 0.2021 1.3273 4.3872 2.4667 83.9105 451.6806 0.2073 1.0004 
0.04 0.1513 0.1936 1.3362 4.6606 2.6203 88.9824 422.4349 0.2254 1.0001 
0.06 0.1498 0.1796 1.3518 4.9297 2.7716 93.8495 401.1301 0.2366 1.0002 
0.08 0.1485 0.1673 1.3645 5.2017 2.9244 98.7843 377.4206 0.2564 0.9997 
0.10 0.1467 0.1495 1.3844 5.4658 3.0730 103.4326 357.7715 0.2746 1.0000 
PAIM-8 
0.01 0.1537 0.2150 1.3121 4.2859 2.4095 82.1948 475.2721 0.1855 0.9998 
0.02 0.1527 0.2066 1.3222 4.4515 2.5028 85.2185 463.1834 0.1864 1.0003 
0.04 0.1514 0.1945 1.3361 4.7837 2.6898 91.3495 430.0219 0.2027 1.0007 
0.06 0.1496 0.1783 1.3532 5.1187 2.8779 97.4206 399.3524 0.2225 1.0002 
0.08 0.1484 0.1664 1.3667 5.4470 3.0626 103.4230 375.1530 0.2382 1.0006 
0.10 0.1469 0.1513 1.3810 5.7871 3.2531 109.5528 352.4195 0.2561 0.9989 
PAIM-9 
0.01 0.1537 0.2146 1.3119 4.2986 2.4165 82.4319 462.4726 0.2001 0.9993 
0.02 0.1528 0.2070 1.3214 4.4734 2.5150 85.6466 445.8990 0.2069 1.0001 
0.04 0.1517 0.1967 1.3318 4.8331 2.7170 92.3348 414.3268 0.2218 0.9993 
0.06 0.1503 0.1850 1.3463 5.1796 2.9123 98.7164 387.6601 0.2369 1.0006 
0.08 0.1494 0.1778 1.3566 5.5205 3.1047 105.0594 366.1289 0.2483 1.0023 





















0.00 0.1393 0.1605 1.5460 3.9064 2.2339 74.0833 580.2555 0.1255 1.0000 
0.01 0.1389 0.1568 1.5497 4.0197 2.2986 76.1779 565.9824 0.1279 0.9995 
0.02 0.1384 0.1504 1.5568 4.1330 2.3631 78.2239 551.3063 0.1312 0.9990 
0.04 0.1378 0.1448 1.5638 4.3542 2.4897 82.3230 522.8142 0.1389 0.9991 
0.06 0.1371 0.1365 1.5727 4.5793 2.6181 86.4392 494.9934 0.1484 0.9983 
0.08 0.1363 0.1272 1.5822 4.8063 2.7475 90.5615 471.1396 0.1568 0.9972 
0.10 0.1355 0.1169 1.5928 5.0338 2.8770 94.6619 449.2968 0.1655 0.9960 
PAIM-2 
0.01 0.1392 0.1596 1.5472 4.0255 2.3021 76.3289 579.3780 0.1187 1.0000 
0.02 0.1389 0.1564 1.5513 4.1440 2.3698 78.5257 560.6900 0.1238 1.0001 
0.04 0.1385 0.1536 1.5556 4.3790 2.5045 82.9337 531.5112 0.1303 1.0007 
0.06 0.1382 0.1499 1.5602 4.6160 2.6400 87.3597 501.3955 0.1398 1.0008 
0.08 0.1377 0.1448 1.5665 4.8524 2.7752 91.7411 474.7798 0.1493 1.0008 
0.10 0.1372 0.1393 1.5729 5.0898 2.9109 96.1265 451.3386 0.1583 1.0006 
PAIM-3 
0.01 0.1390 0.1577 1.5487 4.0194 2.2984 76.1853 569.1968 0.1257 0.9995 
0.02 0.1383 0.1495 1.5582 4.1320 2.3627 78.1927 553.6098 0.1297 0.9992 
0.04 0.1377 0.1434 1.5654 4.3545 2.4898 82.3059 524.7778 0.1374 0.9990 
0.06 0.1370 0.1346 1.5743 4.5815 2.6192 86.4485 498.4611 0.1453 0.9979 
0.08 0.1362 0.1262 1.5831 4.8072 2.7479 90.5615 476.1012 0.1520 0.9970 
0.10 0.1357 0.1202 1.5896 5.0312 2.8758 94.6728 458.2775 0.1559 0.9965 






















0.00 0.1393 0.1605 1.5460 3.9064 2.2339 74.0833 580.2555 0.1255 1.0000 
0.01 0.1389 0.1559 1.5509 4.0379 2.3089 76.5078 562.7173 0.1290 0.9995 
0.02 0.1383 0.1499 1.5574 4.1693 2.3839 78.9048 545.8134 0.1329 0.9990 
0.04 0.1377 0.1439 1.5651 4.4263 2.5310 83.6707 513.1970 0.1422 0.9992 
0.06 0.1369 0.1342 1.5757 4.6874 2.6799 88.4385 483.2012 0.1524 0.9985 
0.08 0.1350 0.1225 1.5877 4.9516 2.8305 93.2163 456.3501 0.1629 0.9971 
0.10 0.1344 0.1037 1.6061 5.2224 2.9841 97.9664 431.9558 0.1739 0.9945 
PAIM-5 
0.01 0.1387 0.1541 1.5521 4.0246 2.3012 76.2292 568.1955 0.1262 0.9988 
0.02 0.1382 0.1485 1.5582 4.1399 2.3669 78.3273 550.5858 0.1314 0.9984 
0.04 0.1374 0.1393 1.5681 4.3705 2.4984 82.5410 520.3800 0.1401 0.9976 
0.06 0.1369 0.1337 1.5744 4.5987 2.6288 86.7576 493.7404 0.1485 0.9972 
0.08 0.1362 0.1244 1.5834 4.8323 2.7618 91.0022 470.3091 0.1561 0.9958 
0.10 0.1353 0.1145 1.5937 5.0639 2.8937 95.1852 448.5179 0.1646 0.9948 
PAIM-6 
0.01 0.1387 0.1541 1.5522 4.0318 2.3053 76.3653 567.9824 0.1259 0.9989 
0.02 0.1381 0.1467 1.5602 4.1557 2.3759 78.5982 549.8325 0.1310 0.9982 
0.04 0.1373 0.1388 1.5693 4.3989 2.5148 83.0697 518.4728 0.1399 0.9979 
0.06 0.1366 0.1309 1.5784 4.6415 2.6534 87.5189 492.2323 0.1473 0.9976 
0.08 0.1361 0.1253 1.5853 4.8821 2.7910 91.9565 467.2369 0.1560 0.9977 
0.10 0.1355 0.1173 1.5935 5.1273 2.9308 96.4300 445.2233 0.1639 0.9969 






















0.00 0.1393 0.1605 1.5460 3.9064 2.2339 74.0833 580.2555 0.1255 1.0000 
0.01 0.1388 0.1550 1.5515 4.0149 2.2957 76.0584 565.9095 0.1283 0.9992 
0.02 0.1385 0.1518 1.5555 4.1200 2.3558 78.0002 551.4223 0.1319 0.9992 
0.04 0.1380 0.1467 1.5620 4.3295 2.4757 81.8852 522.5358 0.1406 0.9994 
0.06 0.1374 0.1407 1.5694 4.5388 2.5954 85.7431 498.2653 0.1479 0.9994 
0.08 0.1368 0.1337 1.5774 4.7494 2.7157 89.6017 474.0378 0.1573 0.9991 
0.10 0.1359 0.1220 1.5886 4.9682 2.8400 93.5190 451.3469 0.1673 0.9973 
PAIM-8 
0.01 0.1391 0.1587 1.5485 4.0358 2.3080 76.5097 564.8399 0.1275 1.0001 
0.02 0.1389 0.1568 1.5509 4.1651 2.3819 78.9315 551.0757 0.1290 1.0002 
0.04 0.1383 0.1508 1.5580 4.4246 2.5303 83.7524 518.3843 0.1377 1.0001 
0.06 0.1377 0.1448 1.5656 4.6822 2.6777 88.5239 487.9734 0.1477 1.0002 
0.08 0.1371 0.1374 1.5741 4.9415 2.8258 93.2911 461.2044 0.1576 0.9999 
0.10 0.1362 0.1262 1.5852 5.2076 2.9774 98.1059 436.7815 0.1677 0.9984 
PAIM-9 
0.01 0.1390 0.1577 1.5499 4.0430 2.3122 76.6329 565.1664 0.1269 1.0003 
0.02 0.1384 0.1522 1.5566 4.1808 2.3909 79.1577 548.4095 0.1302 1.0003 
0.04 0.1379 0.1467 1.5631 4.4563 2.5484 84.2827 514.1080 0.1394 1.0001 
0.06 0.1372 0.1388 1.5720 4.7329 2.7064 89.3783 483.1997 0.1493 0.9996 
0.08 0.1366 0.1318 1.5797 5.0095 2.8644 94.4743 457.2147 0.1577 0.9991 




Table1.4: The correlation coefficient (γ) and correlation equations between some acoustical parameters and  
                 concentrations (C) of imidazolinone derivatives in DMF and DMSO at 308.15K. 
 
Parameters γ Correlation equation γ Correlation equation γ Correlation equation
DMF 
 PAIM-1 PAIM-2 PAIM-3 
κs(cm2.dyn-1) 0.9913 κs+ 4.1389C= 5.4136 0.9926 κs+ 2.8117C= 5.3963 0.9863 κs+ 3.386C= 5.416 
Lf (Ao) 0.9906 Lf+ 0.1745C= 0.4476 0.9931 Lf+ 0.1179C= 0.4468 0.9854 Lf+ 0.1422C= 0.4476 
Z (g.cm-2) 0.9901 Z- 0.6299C= 1.3066 0.9943 Z- 0.4291C= 1.3085 0.9896 Z- 0.4976C= 1.3066 
W (cm-1.dyn-1) 1.0000 W- 7.9005C= 2.3151 0.9998 W- 8.5016C= 2.3189 1.0000 W- 8.0181C= 2.3145 
b (cm3.mol-1) 0.9998 b- 257.83C= 79.099 0.9997 b- 282.02C= 79.172 1.0000 b- 264.03C= 79.072 
Rm (cm-8/3.s-1/3) 0.9999 Rm- 14.0220C= 4.1176 0.9997 Rm- 15.09C= 4.1255 0.9999 Rm- 14.254C= 4.1165
r 0.9864 r+ 0.5234C= 0.2209 0.9863 r+ 0.3382C= 0.2170 0.9711 r+0.4373C= 0.2207 
 PAIM-4 PAIM-5 PAIM-6 
κs(cm2.dyn-1) 0.9756 κs+ 4.5168C= 5.4359 0.9853 κs+ 4.0509C= 5.4092 0.9535 κs+ 4.5197C= 5.3626 
Lf (Ao) 0.9751 Lf+ 0.1904C= 0.4484 0.9856 Lf+ 0.1707C= 0.4473 0.9556 Lf+ 0.1912C= 0.4454 
Z (g.cm-2) 0.9801 Z- 0.6641C= 1.3040 0.9895 Z- 0.6135C= 1.3074 0.9708 Z- 0.6965C= 1.3129 
W (cm-1.dyn-1) 1.0000 W- 9.3230C= 2.3132 1.0000 W- 8.0901C= 2.3153 0.9998 W- 8.5932C= 2.3199 
b (cm3.mol-1) 1.0000 b- 304.88C= 79.088 1.0000 b- 364.5C= 79.091 0.9999 b- 279.84C= 79.1440 
Rm (cm-8/3.s-1/3) 0.9999 Rm- 16.581C= 4.1136 1.0000 Rm- 14.363C= 4.1181 0.9998 Rm- 15.252C= 4.1274
r 0.9631 r+0.5994C= 0.2239 0.9794 r+ 0.5136C= 0.2198 0.9425 r+ 0.5795C= 0.2126 
 PAIM-7 PAIM-8 PAIM-9 
κs(cm2.dyn-1) 0.9929 κs+ 4.9622C= 5.4013 0.9979 κs+ 5.0780C= 5.4138 0.9930 κs+ 4.0206C= 5.4027 
Lf (Ao) 0.9930 Lf+ 0.2102C= 0.4470 0.9982 Lf+ 0.2149C= 0.4475 0.9936 Lf +0.1694C= 0.4470 
Z (g.cm-2) 0.9922 Z- 0.7365C= 1.3083 0.9983 Z- 0.7518C= 1.3065 0.9952 Z- 0.6040C= 1.3078 
W (cm-1.dyn-1) 1.0000 W- 7.6018C= 2.3148 1.0000 W- 9.3690C= 2.3151 0.9999 W- 9.8710C= 2.3176 
b (cm3.mol-1) 0.9999 b- 245.23C= 79.064 1.0000 b- 304.54C= 79.111 0.9999 b- 324.74C= 79.16 
Rm (cm-8/3.s-1/3) 1.0000 Rm- 13.525C= 4.1170 1.0000 Rm- 16.6680C= 4.1176 0.9999 Rm- 17.537C= 4.1228
r 0.9930 r+ 0.6756C= 0.2192 0.9982 r+ 0.6886C= 0.2207 0.9940 r+ 0.5151C= 0.2184 




Parameters γ Correlation equation γ Correlation equation γ Correlation equation 
DMSO 
 PAIM-1 PAIM-2 PAIM-3 
κs(cm2.dyn-1) 0.9966 κs+ 2.3211C= 4.4116 0.9924 κs+ 1.2799C= 4.4159 0.9887 κs+ 2.2493C= 4.4075 
Lf (Ao) 0.9964 Lf+ 0.1077C= 04040 0.9922 Lf+ 0.0590C= 0.4041 0.9893 Lf+ 0.1043C= 0.4038 
Z (g.cm-2) 0.9970 Z- 0.4602C= 1.5459 0.9936 Z- 0.2673C= 1.5453 0.9894 Z- 0.4450C= 1.5468 
W (cm-1.dyn-1) 1.0000 W- 6.4214C= 2.2339 1.0000 W- 6.7653C= 2.2342 1.0000 W- 6.4189C= 2.2340 
b (cm3.mol-1) 1.0000 b- 205.64C= 74.103 1.0000 b- 220.34C= 74.1130 1.0000 b- 205.80C= 74.0930 
Rm (cm-8/3.s-1/3) 1.0000 Rm- 11.255C= 3.9062 1.0000 Rm- 11.8250C= 3.9068 1.0000 Rm- 11.2500C= 3.9064
r 0.9944 r+ 0.4251C= 0.1607 0.9879 r+ 0.2085C= 0.1612 0.9917 r+ 0.4110C= 0.1599  
 PAIM-4 PAIM-5 PAIM-6 
κs(cm2.dyn-1) 0.9831 κs+ 2.8581C= 4.4189 0.9925 κs+ 2.3426C= 4.4015 0.9822 κs+ 2.3070C= 4.3958 
Lf (Ao) 0.9819 Lf+ 0.1313C= 0.4043 0.9929 Lf+ 0.1088C= 0.4035 0.9831 Lf+ 0.1071C= 0.4032 
Z (g.cm-2) 0.9834 Z- 0.5711C= 1.5446 0.9941 Z- 0.4584C= 1.5477 0.9873 Z- 0.4660C= 1.5486 
W (cm-1.dyn-1) 1.0000 W- 7.4808C= 2.2333 1.0000 W- 6.5874C= 2.2347 1.0000 W- 6.9541C= 2.2356 
b (cm3.mol-1) 1.0000 b- 238.70C= 74.1130 1.0000 b- 210.98C= 74.1030 1.0000 b- 223.15C= 74.1210 
Rm (cm-8/3.s-1/3) 0.9999 Rm- 13.1160C= 3.9050 1.0000 Rm- 11.5540C= 3.9078 1.0000 Rm- 12.1790C= 3.9097
r 0.9723 r+ 0.5317C= 0.1622 0.9931 r+ 0.4384C= 0.1587 0.9825 r+ 0.4153= 0.1575 
 PAIM-7 PAIM-8 PAIM-9 
κs(cm2.dyn-1) 0.9904 κs+ 1.9898C= 4.4082 0.9844 κs+ 1.9091C= 4.4223 0.9974 κs+ 2.0729C= 4.4102 
Lf (Ao) 0.9900 Lf+ 0.0922C= 0.4038 0.9836 Lf+ 0.0883C= 0.4044 0.9975 Lf+ 0.0960C= 0.4039 
Z (g.cm-2) 0.9932 Z- 0.4021C= 1.5465 0.9866 Z- 0.3868C= 1.5440 0.9973 Z- 0.4183C= 1.5466 
W (cm-1.dyn-1) 1.0000 W- 6.0369C= 2.2344 1.0000 W- 7.4216C= 2.2335 1.0000 W- 7.8951C= 2.2332 
b (cm3.mol-1) 1.0000 b- 194.00C= 74.1070 1.0000 b- 239.98C= 74.1150 1.0000 b- 254.98C= 74.0770 
Rm (cm-8/3.s-1/3) 1.0000 Rm- 10.5690C= 3.9072 1.0000 Rm- 12.9870C= 3.9053 1.0000 Rm- 13.8190C= 3.9048
r 0.9822 r+ 0.3524C= 0.1599 0.9743 r+ 0.3326C= 0.1626 0.9975 r+ 0.3671C= 0.1607 
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Table 1.5: Bachem’s constants A, B, φok and Sk of imidazolinone derivatives in DMF and DMSO at 308.15K. 
COMPOUNDS A X 1011 
dyn-1.cm3.mol-1
B X 1011 
dyn-1.cm-1/2.mol-3/2
φok X 108 
dyn-1.mol-1
Sk X 108 
dyn-1cm-3/2.mol-3/2
DMF 
PAIM-1 -3.15 4.00 -1.42 1.50 
PAIM-2 -4.95 7.27 -0.90 3.20 
PAIM-3 -1.90 5.78 -1.05 3.50 
PAIM-4 -1.40 10.00 -0.57 6.18 
PAIM-5 -3.10 1.33 -2.20 1.50 
PAIM-6 -10.80 20.00 -7.05 13.33 
PAIM-7 -4.80 1.20 -3.20 2.20 
PAIM-8 -5.30 5.50 -2.92 1.60 
PAIM-9 -5.70 0.67 -3.70 8.13 
DMSO 
PAIM-1 -1.90 1.18 0.01 1.12 
PAIM-2 -0.20 3.50 1.18 1.28 
PAIM-3 -2.80 1.94 -1.10 2.84 
PAIM-4 -2.60 2.18 -0.33 0.30 
PAIM-5 -4.00 5.58 -2.10 6.00 
PAIM-6 -3.80 4.59 -2.10 5.41 
PAIM-7 -3.50 6.57 -1.90 9.09 
PAIM-8 -0.80 3.50 1.30 3.23 
PAIM-9 -1.85 0.94 0.30 0.75 
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 Refractive index is one of the most useful physical parameter to identify an 
unknown compound. Refractive Index along with density, molecular mass and 
specific volume is very useful in the evaluation of various thermodynamics 
properties of chemical materials. It is also useful for the identification of crystalline 
substance. 
 There are various other applications of refractive index also, for example, 
It is used for determining the percentage of sugar in fruits, juices and syrups(1),   
in ion exchange chromatography of inorganic and organic ionic species(2), for 
development and test of an integrated micro system for HPLC separation and 
detection(3). Various workers used this parameter to determine film thickness(4-8) 
also.  
 Literature survey shows that refractive index of various polymer(9-11), 
complex refractive index(12-16), and optical fibers(17-19), solutions(20-22) and other 
materials(23) have been determined. 
By using refractive index Fukuta et al. have been measured concentration 
of refrigerant/ refrigeration oil mixture(24). Bakker et al. determined refractive index 
of printed and unprinted paper(25). Strop and Brunger have been reported 
refractive index-base determination of detergent concentration(26). Ali et al. 
studied the refractive index behavior of α-amino acids and their groups(27). 
Recently Zysk et al. reported the refractive index of carcinogen-induced rat 
mammary tumors(28). 
Much work has been done in liquid mixtures(29-44), but scantly work has 
been reported for the solutions, which includes solutions of organic, inorganic and 
polymeric materials(45-52). 
In this chapter the density and refractive index of all the imidazolinone 
derivatives have been determined in N,N-dimethylformamide (DMF) and 









The solvents DMF and DMSO were of LR grade and are fractionally 
distilled by the reported method(53). All the Schiff bases were recrystalized from 
methanol. For each Schiff base, a series of solutions of different concentrations 
were prepared in both the solvents. The density and refractive index of solutions 
are measured by using Pyknometer and Abbe Refrectometer respectively at 








































RESULTS AND DISCUSSION 
 
 
 The density of solution (ρ12) is related to densities of the solvent, solute 





ρ ρ ρ= +      … (2.1) 
 
where 12ρ  is the density of solution and 1ρ and 2ρ  are the densities of solvent 
and solute respectively. Tables 2.1 and 2.2 show the experimental values of 
densities and refractive index for all the imidazolinone derivatives in N, N-
dimethylformamide (DMF) and dimethylsulfoxide (DMSO) solutions respectively. 
 The density of these imidazolinone derivatives was determined from the 
slope of the plot of 1 121 g ρ verses 2 1g g . Fig. 2.1 shows the plot of 1 121 g ρ  verses 
2 1g g  for PAIM-1 in DMF and DMSO. The inverse of slope gives 2ρ . The 
densities of all the derivatives evaluated from such plots are given in Table 2.3 for 
both DMF and DMSO. Further, by using the following equation (2.2).   
 
A iKM N Vρ = ∆∑        … (2.2) 
  
where ρ is the density of the compound, K is packing fraction (0.599), M is the 
molecular weight of the compound, NA is the Avogadro’s number and ∆Vi is the 
volume increment of the atoms and atomic groups present in the compound.The 
density of all the studied imidazolinone derivatives have been evaluated and 
reported in Table 2.3. The calculated volume increment ∆Vi for different atomic 
groups are given in Table 2.4 
Comparison of densities evaluated from graphs and those calculated from 
eq. (2.2) showed that calculated values are different from those evaluated 
graphically. Also, for the same compound, density in the two solvents is different. 
This suggests that solvent plays an important role. In solutions molecular 
interactions exist which differ in different solvents. This is further confirmed by 
acoustical parameter which is already discussed in Chapter 1. Usually 
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intermolecular interactions do not affect the density but due to the presence of 
different substituted groups in solutes, interaction differs in different solvents 
which may cause change in volume thereby affecting the density of solute in a 
particular solvent. 
 The molar refraction of a pure liquid (MRD)1 can be calculated by the 
following equation: 
 
( ) 221 11
n MMRD
n ρ
 −=  + 
            … (2.3) 
where n, M and ρ are refractive index , molecular weight and density of pure 
liquid respectively. 
 For solutions, the eq. (2.4) was used to determining molar refraction. 
 




n X M X MMRD
n ρ
   − +=    +   
  … (2.4) 
                      
where n12 and ρ12 are refractive index and density of solution respectively. X1 and 
X2 are the mole fractions and M1 and M2 are the molecular weight of the solvent 
and solute respectively.   
 The plots of (MRD)12 verses concentration for all the imidazolinone 
derivatives in DMF and DMSO are given in Fig. 2.2 and 2.3 respectively. It is 
evident from these Fig. that (MRD)12 increase with the increase in concentration. 
From the values of the molar refraction of solution and pure solvent, molar 
refraction of solid compounds were determined by following equation: 
 
( ) ( ) ( )1 212 1 2MRD X MRD X MRD= +   … (2.5) 
                     
 From the density and molar refraction data, the refractive indexes of all the 
compounds were calculated from eq. (2.3). The molar refraction (MRD)2 and 
refractive index of all the compounds are reported in Table 2.5. 
 It is evident from Table 2.5 that both (MRD)2 and refractive index of 
compounds are different in each solvent. This again proves that in different 
solvents, intermolecular interactions are different, which affect these parameters. 
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In some solvents, aggregation or hydrogen bonding takes place whereas in 
others, breakage of bonds takes place. As refractive index and molar refraction 
depends not only upon atomic refraction but also upon single, double or triple 
bonds, these parameters are affected by the type of interactions taking place in 
solution. However, it is reported that bond refraction is more effective than atomic 
refraction. Further, bond polarity also causes change in molar refraction. Thus, 










































Figure 2.1: The variation of 1/g1ρ12 with g2/g1 for PAIM-1 in [A] DMF and  
                    [B] DMSO at 308.15 K. 
 
 




































Figure 2.2: The plots of molar refraction (MRD)12 against concentration of  






































Figure 2.3: The plots of molar refraction (MRD)12 against concentration of  






































Table 2.1: The density (ρ12) and refractive index (n) of imidazolinone    




g1 g2 n 
PAIM-1 
0.00 0.9249 1.0000 0.0000 1.4310 
0.01 0.9268 0.9944 0.0056 1.4320 
0.02 0.9285 0.9888 0.0112 1.4330 
0.04 0.9301 0.9776 0.0224 1.4340 
0.06 0.9328 0.9664 0.0336 1.4350 
0.08 0.9357 0.9554 0.0446 1.4360 
0.10 0.9393 0.9444 0.0556 1.4370 
PAIM-2 
0.01 0.9254 0.9942 0.0058 1.4320 
0.02 0.9266 0.9884 0.0116 1.4330 
0.04 0.9277 0.9768 0.0232 1.4340 
0.06 0.9288 0.9652 0.0348 1.4350 
0.08 0.9325 0.9538 0.0462 1.4360 
0.10 0.9357 0.9424 0.0576 1.4370 
PAIM-3 
0.01 0.9254 0.9944 0.0056 1.4320 
0.02 0.9270 0.9887 0.0113 1.4330 
0.04 0.9292 0.9775 0.0225 1.4340 
0.06 0.9312 0.9664 0.0336 1.4350 
0.08 0.9327 0.9552 0.0448 1.4360 
0.10 0.9338 0.9441 0.0559 1.4370 
PAIM-4 
0.01 0.9251 0.9940 0.0060 1.4320 
0.02 0.9283 0.9879 0.0121 1.4330 
0.04 0.9300 0.9759 0.0241 1.4340 
0.06 0.9332 0.9640 0.0360 1.4340 
0.08 0.9342 0.9521 0.0479 1.4350 
0.10 0.9361 0.9402 0.0598 1.4360 
PAIM-5 
0.01 0.9257 0.9943 0.0057 1.4320 
0.02 0.9277 0.9886 0.0114 1.4330 
0.04 0.9313 0.9774 0.0226 1.4340 
0.06 0.9332 0.9661 0.0339 1.4340 
0.08 0.9356 0.9550 0.0450 1.4360 
0.10 0.9375 0.9438 0.0562 1.4370 













g1 g2 n 
PAIM-6 
0.00 0.9249 1.0000 0.0000 1.4310 
0.01 0.9257 0.9941 0.0059 1.4320 
0.02 0.9284 0.9883 0.0117 1.4340 
0.04 0.9307 0.9767 0.0233 1.4350 
0.06 0.9335 0.9651 0.0349 1.4360 
0.08 0.9373 0.9537 0.0463 1.4370 
0.10 0.9396 0.9422 0.0578 1.4380 
PAIM-7 
0.01 0.9267 0.9945 0.0055 1.4320 
0.02 0.9287 0.9890 0.0110 1.4330 
0.04 0.9300 0.9781 0.0219 1.4340 
0.06 0.9328 0.9673 0.0327 1.4350 
0.08 0.9346 0.9564 0.0436 1.4360 
0.10 0.9382 0.9458 0.0542 1.4370 
PAIM-8 
0.01 0.9256 0.9939 0.0061 1.4320 
0.02 0.9277 0.9878 0.0122 1.4330 
0.04 0.9304 0.9757 0.0243 1.4340 
0.06 0.9330 0.9636 0.0364 1.4350 
0.08 0.9356 0.9516 0.0484 1.4360 
0.10 0.9369 0.9396 0.0604 1.4380 
PAIM-9 
0.01 0.9252 0.9938 0.0062 1.4320 
0.02 0.9274 0.9876 0.0124 1.4330 
0.04 0.9287 0.9752 0.0248 1.4340 
0.06 0.9321 0.9629 0.0371 1.4350 
0.08 0.9351 0.9507 0.0493 1.4360 
0.10 0.9364 0.9384 0.0616 1.4370 
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Table 2.2: The density (ρ12) and refractive index (n) of imidazolinone    




g1 g2 n 
PAIM-1 
0.00 1.0546 1.0000 0.0000 1.4750 
0.01 1.0548 0.9951 0.0049 1.4760 
0.02 1.0556 0.9901 0.0099 1.4770 
0.04 1.0569 0.9802 0.0198 1.4780 
0.06 1.0578 0.9704 0.0296 1.4790 
0.08 1.0585 0.9606 0.0394 1.4800 
0.10 1.0593 0.9507 0.0493 1.4810 
PAIM-2 
0.01 1.0548 0.9949 0.0051 1.4760 
0.02 1.0556 0.9898 0.0102 1.4770 
0.04 1.0568 0.9796 0.0204 1.4780 
0.06 1.0576 0.9694 0.0306 1.4790 
0.08 1.0587 0.9593 0.0407 1.4800 
0.10 1.0596 0.9492 0.0508 1.4810 
PAIM-3 
0.01 1.0547 0.9951 0.0049 1.4760 
0.02 1.0560 0.9901 0.0099 1.4770 
0.04 1.0571 0.9803 0.0197 1.4780 
0.06 1.0577 0.9704 0.0296 1.4790 
0.08 1.0585 0.9606 0.0394 1.4800 
0.10 1.0592 0.9507 0.0493 1.4810 
PAIM-4 
0.01 1.0550 0.9947 0.0053 1.4770 
0.02 1.0557 0.9894 0.0106 1.4780 
0.04 1.0572 0.9788 0.0212 1.4790 
0.06 1.0584 0.9683 0.0317 1.4800 
0.08 1.0593 0.9577 0.0423 1.4810 
0.10 1.0603 0.9472 0.0528 1.4820 
PAIM-5 
0.01 1.0547 0.9950 0.0050 1.4760 
0.02 1.0554 0.9900 0.0100 1.4770 
0.04 1.0564 0.9801 0.0199 1.4780 
0.06 1.0572 0.9701 0.0299 1.4790 
0.08 1.0576 0.9601 0.0399 1.4800 
0.10 1.0585 0.9502 0.0498 1.4810 













g1 g2 n 
PAIM-6 
0.00 1.0546 1.0000 0.0000 1.4750 
0.01 1.0548 0.9949 0.0051 1.4760 
0.02 1.0556 0.9897 0.0103 1.4770 
0.04 1.0569 0.9795 0.0205 1.4780 
0.06 1.0582 0.9692 0.0308 1.4790 
0.08 1.0594 0.9590 0.0410 1.4800 
0.10 1.0601 0.9488 0.0512 1.4820 
PAIM-7 
0.01 1.0549 0.9952 0.0048 1.4760 
0.02 1.0556 0.9904 0.0096 1.4770 
0.04 1.0568 0.9807 0.0193 1.4780 
0.06 1.0581 0.9711 0.0289 1.4790 
0.08 1.0592 0.9616 0.0384 1.4800 
0.10 1.0596 0.9520 0.0480 1.4810 
PAIM-8 
0.01 1.0551 0.9946 0.0054 1.4760 
0.02 1.0556 0.9893 0.0107 1.4770 
0.04 1.0567 0.9786 0.0214 1.4790 
0.06 1.0581 0.9679 0.0321 1.4800 
0.08 1.0593 0.9573 0.0427 1.4810 
0.10 1.0599 0.9466 0.0534 1.4820 
PAIM-9 
0.01 1.0555 0.9945 0.0055 1.4760 
0.02 1.0566 0.9891 0.0109 1.4770 
0.04 1.0576 0.9782 0.0218 1.4780 
0.06 1.0587 0.9673 0.0327 1.4790 
0.08 1.0596 0.9565 0.0435 1.4800 


















Table 2.3: Experimental and calculated densities of imidazolinone    
                  derivatives in DMF and DMSO Solutions at 308.15 K. 
 











PAIM-1 1.2513 1.1637 1.2018 
PAIM-2 1.1444 1.1660 1.2170 
PAIM-3 1.1275 1.1596 1.2018 
PAIM-4 1.1673 1.1786 1.1849 
PAIM-5 1.2285 1.1410 1.2472 
PAIM-6 1.2794 1.1827 1.2578 
PAIM-7 1.2226 1.1801 1.1952 
PAIM-8 1.1174 1.1700 1.2559 




































































































































































































































































Table 2.5: Molar refraction (MRD)2 and refractive index (n) of   






(MRD)2 n (MRD)2 n 
PAIM-1 156 1.6660 166.5 1.6598 
PAIM-2 183.75 1.7042 172 1.6626 
PAIM-3 151.5 1.5643 164 1.6443 
PAIM-4 164.5 1.5970 184 1.6960 
PAIM-5 142 1.5728 169 1.6487 
PAIM-6 181 1.7914 175.5 1.6862 
PAIM-7 145.5 1.6122 167 1.6972 
PAIM-8 166.25 1.5728 191.5 1.7256 
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 Electrical conductance is a property of ionic solution. The conductance of 
electrolytic solutions depends on the concentration of the ions and also on the 
nature of the ions present (through their charges and mobilities. This property is 
useful for physico-chemical analysis. By conductometry, one can determine the 
dissociation constants, solubilities and rate of reactions. 
 Conductometry method is also useful to determine the purity of water, 
amount of nitrogen in biological materials etc(1), micro amounts of carbon in 
aqueous phase(2) and for determining of graphite in propellants(3). Various 
workers used this technique to determine microgram quantities of ammonia(4), 
liquid film thickness in two phase flow(5), thermodynamic successive ionization 
constants of chloranilic acid(6), ascorbic acid in vitamin C tablet(7), carbon in 
uranium carbide and its solution in nitric acid(8) etc. It is also used to study 
enzymatic degradation of microbial biofilm(9) and streptococcus thermophilus 
(lactic bacteria)(10), the monomer reactivity ratios for copolymerization of itaconic 
acid and acrylamide(11), dye-surfactant ion pair formation in aqueous solution(12), 
ionic conductance of polymeric electrolytes and of polymeric composite solid 
electrolyres(13), the electrolyte and osmotic permeability coefficients(14), biogenic 
amines(cadaverine, putrescine, agmatine, histamine, tryptamine and tyramine)(15) 
etc. An indirect conductometric screening method has been reported for the 
detection of antibiotic residues in bovine kidneys(16). Sawai et al.(17) have used 
this technique to investigate the growth of fungi. 
Literature survey shows that conductance of various many inorganic and 
organic compounds have been measured in aqueous(18-31) conductance of and 
non-aqueous solvents(32-35).    
  Thus, in present work, conductance of imidazolinone derivatives are 
measured in N,N-dimethylformamide (DMF) and dimethylsulfoxide (DMSO) at 
308.15 K. The selection of these two solvents is due to their dipolar aprotic 






All the solvents used were distilled prior to use. The solutions of different 
concentrations were prepared for each Schiff base in DMF and DMSO and the 
conductance of each solution was measured by using Systronics Conductivity 
Meter (Model No. 306) having cell constant 0.85 cm-1 at 308.15 K. The measured 









































RESULTS AND DISCUSSION 
 
 The measured conductance (k) of each solution after correction was used 
to determine the specific conductance (κ), which is then used for the calculation 
of equivalent conductance (λc).  
The equations used for calculating specific conductance (κ) and equivalent 
conductance (λc) are: 
                                  k κθ=      ….. (3.1) 
                             1000c C
κλ =      ….. (3.2) 
where θ is the cell constant (= 0.85) and c is the concentration (g.equi./lit.) of 
solution. 
 These equivalent conductance values of all the imidazolinone derivatives 
in DMF and DMSO at 308.15K are reported in Tables 3.1 and 3.2 along with 
measured conductance (k). In DMSO, the relatively low conductivities are due to 
greater electro relaxation effect owing to the higher permittivity of DMSO, which 
contributes interionic repulsions to a larger extent(37). It is observed that for all the 
systems studied, conductance increases with concentration (as also shown in 
Fig. 3.1 and 3.2).  
The equivalent conductance (λc) is plotted against √C for all imidazolinone 
derivatives and is shown in Fig. 3.3 and 3.4. It is obvious from figures that all 
derivatives behave as weak electrolytes in DMF. For all the imidazolinone 
derivatives, the equivalent conductance increases in DMF uninterruptedly (except 
for PAIM-1) with decreasing concentration.  
 The order of λc in DMF is: PAIM-8 > PAIM-6 > PAIM-3 > PAIM-1 > PAIM-7 
> PAIM-9 > PAIM-4 > PAIM-2 > PAIM-5. In Case of PAIM-1, as concentration 
decreases, λc increases and at 0.004M, it suddenly drops but again increases 
with further increases in concentration. 
 In DMSO, at lower concentration, λc is almost constant for PAIM-1, PAIM-
5, PAIM-6 and PAIM-7. Then, it decreases with increasing concentration. For 
PAIM-2, PAIM-3 and PAIM-8, it decreases continuously (except at 0.001M for 
PAIM-2 and PAIM-3) with increasing concentration. However, for PAIM-4 and 
PAIM-9, the nature of plot is interesting. The curves increase with decreasing 
concentration but after reaching to a certain maximum value, it bends downwards 
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at very low concentration. Such behavior was also reported by Singh et al. while 
studying conductance of polyions(38). It is reported that such decrease with 
increasing concentration is due to an increased screening of charges through 
counterion associations. The intramolecular coulombic interactions may also be 
affecting the conductance of these compounds in DMSO(39). 
 For weak electrolytes, it is difficult to determine λ0. However, in the studied 
solutions of compounds, λ0 values are evaluated approximately by extrapolation 
method. These values are compared with those determined by an alternate 
procedure using the following equation. 
                                      ( )0 0 ck k c cλ φ= + +   ….. (3.3) 
where k and k0 are the electrolytic conductivity of the solutions and solvent 
respectively. c is the equivalent concentration and the function Φ(c) denotes the 
effect of interionic interactions. The limiting conductivity can be determined 
accurately from the slope, dk/dc of plot of k verses c, provided other derivatives 
(dk0/dc) and d[cΦ(c)]/dc in differential form of equation (3.3) are neglected as 
compared to λ0, which can be determined from differential form of equation (3.3) 
is  




  = + +                ….. (3.4) 
 These λ0 values are reported in Table 3.3 along with those determined by 
extrapolation. 
  From Table 3.3, it is observed that in case of DMF, the calculated values 
are much different than those observed from extrapolation. 
 The deviation between these λ0 values suggest the presence of interionic 
interactions in DMF, which should not be ignored. For PAIM-3 and PAIM-8, λ0 
values could not be evaluated due to very weak nature of compounds. 
 However, in DMSO, the calculated values of λ0 from equation (3.3) are in 
good agreement except for PAIM-7 and PAIM-8. For PAIM-4 and PAIM-9, it could 
not be compared due to bending nature of λc vs √C plot. 
 Thus, for the studied compounds, the above used method is not applicable 




Figure 3.1:  The variation of Conductance (κ) with concentration for   



























































Figure 3.2:  The variation of Conductance (κ) with concentration for  

























































Figure 3.3:  The variation of equivalent conductance (λC) with √C for  






























































Figure 3.4: The variation of equivalent conductance (λC) with √C for    




























































Table 3.1: The Conductance (C) and equivalent conductance (λC) of  


















 PAIM-1 PAIM-2 PAIM-3 
0.000 4.6  4.6  4.6  
0.001 5.3 5.8800 5.2 5.0400 5.4 6.7200 
0.002 5.9 5.4600 5.6 4.2000 5.8 5.0400 
0.004 6.6 4.2000 6.1 3.1500 6.4 3.7800 
0.006 8.1 4.9000 6.6 2.8000 7.0 3.3600 
0.008 9.2 4.8300 7.0 2.5200 7.6 3.1500 
0.010 9.9 4.4520 7.5 2.4360 8.0 2.8560 
0.020 11.1 2.7300 9.5 2.0580 9.9 2.2260 
0.040 13.9 1.9530 13.5 1.8690 13.2 1.8060 
0.060 16.5 1.6660 17.0 1.7360 16.3 1.6380 
0.080 19.7 1.5855 20.0 1.6170 19.2 1.5330 
0.100 25.7 1.7724 23.0 1.5456 21.7 1.4364 
 PAIM-4 PAIM-5 PAIM-6 
0.001 5.2 5.0400 5.0 3.3600 5.4 6.7200 
0.002 5.6 4.2000 5.2 2.5200 6.0 5.8800 
0.004 6.1 3.1500 5.4 1.6800 7.0 5.0400 
0.006 6.7 2.9400 5.6 1.4000 7.8 4.4800 
0.008 7.3 2.8350 5.8 1.2600 8.5 4.0950 
0.010 7.6 2.5200 6.1 1.2600 9.2 3.8640 
0.020 9.9 2.2260 7.1 1.0500 12.6 3.3600 
0.040 14.5 2.0790 8.9 0.9030 17.5 2.7090 
0.060 18.7 1.9740 10.4 0.8120 22.5 2.5060 
0.080 21.9 1.8165 11.6 0.7350 26.1 2.2575 
0.100 25.0 1.7136 13.1 0.7140 29.3 2.0748 
 PAIM-7 PAIM-8 PAIM-9 
0.001 5.3 5.8800 5.5 7.5600 5.3 5.8800 
0.002 5.7 4.6200 6.1 6.3000 5.5 3.7800 
0.004 6.4 3.7800 7.0 5.0400 5.8 2.5200 
0.006 7.0 3.3600 7.7 4.3400 6.1 2.1000 
0.008 7.6 3.1500 8.2 3.7800 6.4 1.8900 
0.010 8.2 3.0240 8.6 3.3600 6.8 1.8480 
0.020 10.4 2.4360 11.2 2.7720 7.6 1.2600 
0.040 14.5 2.0790 16.3 2.4570 8.2 0.7560 
0.060 18.2 1.9040 20.8 2.2680 9.2 0.6440 
0.080 21.8 1.8060 24.7 2.1105 10.5 0.6195 







Table 3.2: The Conductance (C) and equivalent conductance (λC) of  


















 PAIM-1 PAIM-2 PAIM-3 
0.000 0.4  0.4  0.4  
0.001 0.5 0.8400 0.6 1.6800 0.6 1.6800 
0.002 0.6 0.8400 0.9 2.1000 0.9 2.1000 
0.004 0.8 0.8400 1.3 1.8900 1.5 2.3100 
0.006 1.0 0.8400 1.7 1.8200 2.0 2.2400 
0.008 1.2 0.8400 2.1 1.7850 2.4 2.1000 
0.010 1.4 0.8400 2.5 1.7640 2.8 2.0160 
0.020 2.3 0.7980 4.3 1.6380 5.0 1.9320 
0.040 3.9 0.7350 7.4 1.4700 8.6 1.7220 
0.060 5.6 0.7280 10.5 1.4140 12.4 1.6800 
0.080 7.2 0.7140 13.1 1.3335 14.7 1.5015 
0.100 8.8 0.7056 15.3 1.2516 17.9 1.4700 
 PAIM-4 PAIM-5 PAIM-6 
0.001 0.5 0.8400 0.5 0.8400 0.7 2.5200 
0.002 0.6 0.8400 0.6 0.8400 1.0 2.5200 
0.004 0.8 0.8400 0.8 0.8400 1.5 2.3100 
0.006 1.1 0.9800 1.0 0.8400 2.1 2.3800 
0.008 1.8 1.4700 1.1 0.7350 2.4 2.1000 
0.010 2.0 1.3440 1.3 0.7560 3.1 2.2680 
0.020 3.5 1.3020 2.3 0.7980 5.3 2.0580 
0.040 6.3 1.2390 3.9 0.7350 9.4 1.8900 
0.060 8.8 1.1760 5.3 0.6860 12.8 1.7360 
0.080 11.2 1.1340 7.1 0.7035 15.8 1.6170 
0.100 13.4 1.0920 8.2 0.6552 20.3 1.6716 
 PAIM-7 PAIM-8 PAIM-9 
0.001 0.6 1.6800 0.9 4.2000 0.5 0.8400 
0.002 0.8 1.6800 1.3 3.7800 1.0 2.5200 
0.004 1.2 1.6800 2.1 3.5700 1.7 2.7300 
0.006 1.5 1.5400 2.7 3.2200 2.7 3.2200 
0.008 1.8 1.4700 3.4 3.1500 4.1 3.8850 
0.010 2.1 1.4280 4.0 3.0240 6.8 5.3760 
0.020 3.5 1.3020 6.8 2.6880 9.6 3.8640 
0.040 6.1 1.1970 10.8 2.1840 10.1 2.0370 
0.060 8.7 1.1620 15.0 2.0440 11.8 1.5960 
0.080 10.9 1.1025 18.5 1.9005 14.0 1.4280 
0.100 12.9 1.0500 21.3 1.7556 16.6 1.3608 
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Table 3.3: The limiting equivalent conductance (λ0) of all the Imidazolinone  
















 DMF DMSO 
PAIM-1 7.8 6.82 0.85 0.98 
PAIM-2 6.75 2.45 2.80 2.14 
PAIM-3 - 2.75 - 2.53 
PAIM-4 7.15 2.41 - 1.92 
PAIM-5 5.15 1.28 0.86 0.93 
PAIM-6 9.1 3.95 2.80 2.71 
PAIM-7 7.1 3.13 2.3 1.69 
PAIM-8 - 3.03 4.8 3.78 
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 When a solute is dissolved in a solvent, heat is either absorbed or evolved. 
Thus, dissolution of a solute in a solvent is accompanied by the heat change i.e., 
enthalpy change (∆H) of the system. If the heat is absorbed i.e., the solution is 
cooler then ∆H is positive. If the heat is evolved i.e., the solution is warmer then 
∆H is negative. The heat of solution is defined as the change in enthalpy when 
one mole of substance is dissolved in specified quantity of solvent at a given 
temperature. The heat of solution for many inorganic, organic and polymeric 
compounds has been reported 
(1-14)
. Volynskaya et al. have been studied the heat 
of solution of amorphous polymers 
(15)
. Meurs et al. also studied the heat of 
solution of some polymers (16). Goralski et al. have been reported the heat of 
solution of cholesterol(17). Yonemochi et al. studied the heat of solution of chiral 
drugs(18).  
The molar heat of solution and melting temperature of a substance can be 
determined from the solubility measurements at different temperatures
(19)
. 
The thermodynamic properties of several electrolytes in different solvents 
have been studied by many workers
(20-26)
. In our laboratory, heat of solution of 
some organic compounds has also been determined
(27, 28)
. 
In the present work, heat of solution for some imidazolinone derivatives 
was determined in N,N-dimethylformamide (DMF) and Dimethylsulfoxide (DMSO) 



















           The solvents used for the measurements were purified and fractionally 
distilled prior to use by the method reported in the literature(29). The solubility of 
each Schiff base was determined by transferring 25 ml of saturated solution into 
a pre-weighed 50 ml beaker at a definite temperature. The weight of beaker 
along with solution was taken and the solvent was evaporated to dryness until 
constant weight is obtained. This gives the weight of solute present in 25 ml 
saturated solution. Three replicate measurements were carried out at a particular 
temperature and average value of weight was determined. The experiment was 
repeated at other temperatures also. Subtraction of weight of solute from the 

































RESULTS AND DISCUSSION 
 
The solubility (N2) of Imidazolinone derivatives in DMF and DMSO are 
given in Tables 4.1 and 4.2 respectively. It is evident from the tables that the 
solubility of imidazolinone derivatives increases linearly with temperature in both 
the solvents. Comparison of solubility of these derivatives in DMF and DMSO 
shows that overall solubility is greater in DMSO than in DMF. Thus, the solvent 
polarity plays an important role on the solubility of studied imidazolinone 
derivatives.  
The variation of solubility with temperature is given by; 





∆  =         ….. (4.1) 
where N2 is the solubility or mole fraction, T is absolute temperature of the 
experiment, ∆Hs is the heat of solution and R is the gas constant. Integration of 
equation (4.1) between temperature limits from T and Tm gives 








∆ −  =     ….. (4.2) 
where T = temperature of experiment and Tm = melting temperature. 
 Fig. 4.1 shows the variation of ln N2 with 1/T for imidazolinone derivative 
(PAIM-1) in DMF [A] and DMSO [B] solutions. It is evident from the Fig. 4.1 that 
ln N2 varies linearly with 1/T. The correlation coefficient γ for these plots for all the 
compounds in DMF and DMSO is given in Table 4.3. 
 From these plots and using equation (4.2), ∆Hs values are calculated and 
are reported in Tables 4.1 and 4.2 for DMF and DMSO respectively. It is 
observed that for both solvents, ∆Hs values are positive for all the compounds 












Figure 4.1: The variation of lnN2 against 1/T for PAIM-1 in [A] DMF and [B]    





































Table 4.1: The solubility (N2) and heat of solution (∆Hs) of imidazolinone  





N2. 103 ∆Hs 
(k.cals/mol)
N2. 103 ∆Hs 
(k.cals/mol)
N2. 103 ∆Hs 
(k.cals/mol)
 PAIM-1 PAIM-2 PAIM-3 
308.15 9.2448 17.9109 11.5197 17.7035 14.9958 15.4772 
318.15 9.3556 19.5301 11.6245 19.3809 15.0334 16.8523 
328.15 9.4744 21.3452 11.7293 21.2798 15.1465 18.3656 
 PAIM-4 PAIM-5 PAIM-6 
308.15 10.6579 16.4209 7.9554 19.7023 10.0131 18.3995 
318.15 10.7657 17.8208 8.0802 21.6015 10.1256 20.1498 
328.15 10.8706 19.3779 8.1540 23.7935 10.2245 22.1405 
 PAIM-7 PAIM-8 PAIM-9 
308.15 10.5240 19.2714 2.2237 23.6950 2.9772 22.4819 
318.15 10.6050 21.2427 2.3724 25.6629 3.0587 24.4872 
328.15 10.6602 23.5186 2.4358 28.0433 3.1613 26.7125 
 
 
Table 4.2: The solubility (N2) and heat of solution (∆Hs) of imidazolinone   





N2. 103 ∆Hs 
(k.cals/mol)
N2. 103 ∆Hs 
(k.cals/mol)
N2. 103 ∆Hs 
(k.cals/mol)
 PAIM-1 PAIM-2 PAIM-3 
308.15 10.0360 17.5969 12.3831 17.4168 16.1557 15.2027 
318.15 10.1382 19.1943 12.4938 19.0672 16.2883 16.5304 
328.15 10.2017 21.0063 12.5679 20.9493 16.3552 18.0291 
 PAIM-4 PAIM-5 PAIM-6 
308.15 11.4495 16.1618 8.6891 19.3428 10.8145 18.0917 
318.15 11.5661 17.5388 8.7999 21.2190 10.9371 19.8116 
328.15 11.6599 19.0775 8.8918 23.3650 11.0295 21.7744 
 PAIM-7 PAIM-8 PAIM-9 
308.15 11.4629 18.9097 2.5427 23.1750 3.4009 21.9676 
318.15 11.5650 20.8378 2.6162 25.2475 3.4867 23.9333 













Table 4.3: Correlation coefficient values obtained from plot of ln N2 against 1/T. 
 
 
Correlation coefficient (γ) Compounds 
DMF DMSO 
               PAIM-1 0.9988 0.9860 
PAIM-2 0.9998 0.9903 
PAIM-3 0.9139 0.9707 
PAIM-4 1.0000 0.9977 
PAIM-5 0.9825 0.9985 
PAIM-6 0.9995 0.9957 
PAIM-7 0.9913 1.0000 
PAIM-8 0.9521 0.9992 
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 There are many techniques available with physical chemists and material 
science scientists for obtaining qualitative and quantitative informations about the 
composition, structure and characterization of materials. Among these 
techniques, thermal analysis has grown rapids recently. The importance of 
thermal analysis is increasing day by day because of the advancement of thermal 
analysis technology, relative cheapness of the equipment and the time required 
to achieve the desired result. Thermal analysis serves as a useful tool to follow 
the cource of decomposition of mixed metal precursor and the formation of stable 
phase at different temperature. This technique can provide the measurement of 
overall (global) kinetic parameters of thermally simulated reactions which permit a 
deeper insight in to the mechanism of high energetic compounds. 
 Thermal analysis has used to determine the physical and chemical 
properties of polymers, geological materials and coals (1-3). Both quantitative and 
qualitative analysis can be carried out and one can identify and characterize the 
samples by qualitative investigations of their thermal behaviors. Current areas of 
applications include environmental measurements, composition analysis, product 
reliability, stability, chemical reaction and dynamic properties. Further, various 
reversible and non-reversible reactions(4,5), the decomposition of molecules 
absorbed on a surface, phase transitions etc. can also be studied.  
 There are various types of thermal techniques such as, Differential 
Scanning Calorimetry (DSC), Differential Thermal Analysis (DTA), Thermo 
gravimetric Analysis (TGA), Evolved Gas Detection (EGD), Evolved Gas Analysis 
(EGA) etc. 
 In these techniques, DTA and DSC are based on energy changes 
whereas TGA depends on weight changes. EGD and EGA techniques depend 
upon the evolved volatiles. The parameters measured as function of temperature 
in DTA, DSC, TGA and ECD are temperature difference between sample and 
reference coefficient of volume expansion and mass of evolved gas respectively. 
 In TGA technique, the mass change in a sample is recorded continuously 
as a function of temperature or time when it is subjected to a programmed 
temperature change in specific atmosphere. A derivative of thermo gravimetric 
curve is useful in resolving the partially over lapping steps in the multisteps 
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reactions involving the formation of weakly stable intermediates. By TGA, thermal 
stability, kinetic parameters, compositional analysis etc. can be measured. 
 Literature survey shows that several investigation have been carried out 
on the application of thermal methods in pharmaceutical industry(6-15). Wendlandt 
and Collins(16) used DTA and TG technique for the characterization and 
identification of commercial non prescription analgesics. A number of 
investigators have studied the physical and chemical properties of various 
inorganic, organic and polymeric materials(17-34) by using thermal methods. 
Kinetic study of thermal decomposition of various metal complexes have also 
been reported by several workers(35-44). Khraisha and Shabib reported thermal 
analysis of Shale oil(45). Ihms and Brinkman reported thrmo gravimetric analysis 
as a polymer identification in forensic application(46). Ruiz et al. have been studied 
the effect of temperature on cement paste(47). Wendlandt(48) have applied this 
method (TGA) to study the thermal stability of EDTA as free acid. Further, by 
using this technique, the composition of binary mixtures can also be determined. 
One of the most important applications of thermo gravimetry is in examining the 
thermal stability of polymer and binding materils. 
 Various workers used TGA techniques as a tool in the characterization of 
natural rubber and styrene butadiene blends(49,50). By using TGA, thermal 
properties of epoxy resins(51,52), olive wood(53), fabrics(54) and other materials have 
been reported. 
 In this chapter, thermal properties of some imidazolinone derivatives have 
been studied by using TGA technique.   
From TGA curves, various kinetic parameters can be evaluated by several 
methods. In all these methods, it is assumed that thermal and diffusion barriers 
are negligible because small quantity of material is used. The shape of any TGA 
curve depends on the nature of apparatus and the way in which it is used. 
Further, Arrhenius equation is valid in all these methods. 
  The kinetic treatments are generally based on the relationship of the 
type: 
  dC/dt = K f (C)     ... (5.1) 
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where C is the degree of conversion, t is time and K is rate constant. f(C) 
is a temperature independent function of C. 
The constant K is assumed to have the Arrhenius form: 
  K = A e -E/RT      ... (5.2) 
C  can also be defined as: 
  C = 1-(W/W0)                   ... (5.3) 
where W0 and W are the initial weight at t=0 and weight at any time t of the 
material. 
Equation (7.3) can be written as: 
    (W/W0) = (1-C)     ... (5.4) 
W/ W0 is known as residual weight fraction. 
Thus, the rate of conversion is, 
  dC/dt = - (1/W0) (dW/dt)    ... (5.5) 
For homogeneous kinetics, the conversion is assumed to be of the form: 
  f (C) = (1-C)n      ... (5.6) 
where n is the order of the reaction. 
Substituting the values from equation (5.2) and (5.6) in equation (5.1) 
gives: 
  dC/ dt = A e -E/RT (1-C)n 
or   dC/dt = (A/β) e -E/RT (1-C)n       ... (5.7) 
where A is the frequency factor, β is the rate of heating and E is the 
energy of activation. 
Various methods for single and multiple heating rates have been reported. 





1.   Freeman-Carroll (55) and Anderson-Freeman Method (56): 
At a single heating rate, Freeman and Carroll gave the following relation to 
analysis TGA data : 
 ln (dC/dt)/ln (1-C) = n-E/R [(1/T/(∆ln(1-C)]       ... (5.8) 
A plot of left hand side against (1/T)/(∆ln(1-C)) gives a straight line with a 
slope equal to -E/R and the intercept is equal to n.  
Anderson and Freeman then derived the following equation by using 
equation (4.8): 
 (∆ln[dC/dt]) = n (∆ln(1-C)) - E/R ∆(1/T)       ... (5.9) 
The plot of (∆ln[dC/dt]) against (∆ln(1-C)) for equal intervals of ∆(1/T) gives 
a straight line with slope equal to n and intercept -E/R∆(1/T). 
2. Sharp-Wentworth method (57): 
To analyse the TGA data for first order kinetics (n=1), Sharp and 
Wentworth gave the relation: 
 log [(dC/dt)/(1-C)] = log (A/β) – (E /2.303R).(1/T)  ... (5.10) 
The plot of log [(dC/dt)/(1-C)] against 1/T would be a straight line with 
slope equal to - (E/2.303R) and intercept equal to log (A/β). 
3.  Chatterjee Method(58): 
Based on the weight units, the following relation was developed by 
Chatterjee: 
 n = [log(dW/dt)1-log(dW/dt)2] / (log W1-log W2)        ... (5.11) 
where W1 and W2 are the sample weights.  
4.  Horowitz and Metzger method(59)  : 
In this method, the value of energy of activation E can be determined from 
a single TG curve by the relation: 
 ln [ln(1-C)-1] = (E/RTs2)θ                             ... (5.12) 
 157
where θ = T-Ts. Ts is the temperature at which the rate of decomposition is 
maximum.The frequency factor A and entropy change ∆S can be determined by 
the following equations: 
 ln E - ln (RTs2) = ln A - lnβ  - E/RTs           ... (5.13) 
            A = (kbT / h) e ∆S/R                                ... (5.14) 





























          The Differential Scanning Calorimetry (DSC), Differential thermal analysis 
(DTA) and Thermo gravimetric analysis (TGA) measurements were made on the 
instrument “Universal V2.6D TA Instruments at the heating rate of                  




































RESULT AND DISCUSSION 
 
 The TGA thermo grams of imidazolinone derivatives are given in Fig. 5.1 
to 5.5. Various thermal properties such as initial decomposition temperature 
(IDT), the decomposition temperature range and the maximum degradation along 
with the percentage weight loss and Exo / Endo transitions of imidazolinones are 
reported in Table 5.1. 
 The thermal stability can not be decided by weight loss because for all 
compounds, degradation is multi step process (Fig. 5.1 to 5.5). Each step is of 
different order. Further, the variation in the trend of thermal decomposition might 
be interpreted by taking into account some intermolecular interactions (structural 
as well as electronic) and also because of several experimental factors. However 
one from Table 5.1, one can say that PAIM-4 is most stable whereas PAIM-8 is 
less stable. This suggests that the presence of 1-napthylamine (as in PAIM-4) 
causes greater stability than 3-Cl-4-F-aniline (as in PAIM-8), which is less stable. 
           The kinetic parameters, such as order of the degradation (n), energy of 
activation (E), frequency factor (A) and entropy change (∆S) for each step are 
reported in Tables 5.2 and 5.3.  
It is evident from Tables 5.2 and 5.3 that order of reaction is quite different 
in different steps for different imidazolinone derivatives. For first step, order of 
reaction varies from 2.5 to 21. For second step also, values of n varies from 2.5 
to 6.7.  
In first step, energy of activation (E) is maximum for PAIM-5 and minimum 
for PAIM-4. The frequency factor (A) also varies in the same order i.e., maximum 
for PAIM-5 and minimum for PAIM-4. In second step, energy of activation is 
found to be maximum for PAIM-3 and minimum for PAIM-6. The frequency factor 
A is also maximum for PAIM-3 and minimum for PAIM-6. Comparison of E and A 
values in Tables 5.2 and 5.3 shows that values of E and A are minimum for 
second steps of all the imidazolinone derivatives. 
Further, change in entropy (∆S0) for all these reactions were also 
calculated by equation (5.14). It is observed  that,  change in entropy  are positive  
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for all compounds except PAIM-4 and PAIM-9 for the first step while in second 
step entropy changes are negative for all the imidazolinone derivatives. The 
positive ∆S0 indicates that the transition state is in less ordered state. Whereas 
the negative ∆S0 values indicate that the activation complex has a more ordered 




Thus, the degradation in imidazolinone derivatives is multi step process 
with different order of reaction.  Further, thermal stability depends upon the type 
of substituent present. It is observed that presence of 1-napthylamine (as in 
PAIM-4) increases the stability whereas 3-Cl-4-F-aniline (as in PAIM-8) 















































































































































PAIM-1 4.0279 240 240 – 596 37.7891 1.5221 596 
PAIM-2 5.3698 239 239 – 581 37.3425 2.0052 581 
PAIM-6 5.1339 240 240 – 588 38.4844 1.9758 588 
PAIM-4 5.6007 332 332 – 586 36.2675 2.0313 586 
PAIM-5 5.3908 252 252 – 596 36.3415 1.9591 596 
PAIM-6 4.6280 252 252 – 579 33.3523 1.6920 579 
PAIM-7 4.1518 240 240 – 592 37.3890 1.5523 592 
PAIM-8 4.5548 212 212 – 594 38.9758 1.7753 594 




























Table 5.2: The kinetic parameters for all the imidazolinone derivatives for     










PAIM-1 6.00 239.83 1.54 X 1019 269.25 
PAIM-2 7.00 221.71 5.34 X 1017 241.33 
PAIM-6 5.00 232.22 4.10 X 10 18 258.27 
PAIM-4 8.20 34.44 4.65 -87.37 
PAIM-5 2.50 270.21 5.37 X 10 21 317.92 
PAIM-6 15.00 100.96 3.61 X 107 46.72 
PAIM-7 8.00 203.23 1.48 X 1016 211.52 
PAIM-8 21.00 87.76 1.71 X 106 21.21 





Table 5.3: The kinetic parameters for all the imidazolinone derivatives for  










PAIM-1 6.60 44.56 26.18 -73.01 
PAIM-2 6.30 61.40 415.84 -50.04 
PAIM-6 2.50 119.72 6.77 X 106 -7.50 
PAIM-4 - - - - 
PAIM-5 6.40 42.91 19.39 -75.53 
PAIM-6 6.0 33.81 4.31 -87.95 
PAIM-7 6.70 50.64 77.85 -63.89 
PAIM-8 5.30 92.01 6.94 X 104 -7.37 
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INRODUCTION 
 The constants, which are used to measure the strength of acid or bases 
are known as dissociation constants. These constants are also known as acidity 
constant, ionization constant or formation constant. 
 The dissociation or ionization constant is determined by determining one 
of the species, at equilibrium. The activity or concentration of the others can be 
calculated from the amount of the acid or base initially introduced and the 
stoichiometry of the acid base equilibrium. 
For the measurement of dissociation constants, various methods have 
been developed, such as (i) potentiometry including pH metry(1) (ii) 
spectrophotometry, (iii) conductometry, (iv) solubility measurements(2), (v) 
cryoscopy(3), (vi) measurements of the rates of acid catalyzed hydrolysis of 
esters(4), (vii) measurement of the relative distribution of an acid between two 
immiscible solvents(5) and (viii) magnetic measurements. 
For the very weak acids of pK range between 11 and 14, the method of 
electrical conductance is useful. However, due to more time consuming(6) and 
contamination of carbon dioxide, this method is not widely used. 
When the acid is sparingly soluble and acid strengths are very high or very 
low, spectrophotometer method is considered to be an ideal method but, this 
method is also more time consuming. It is applicable if at least one of the species 
at equilibrium absorbs characteristically in the ultraviolet or visible region and the 
relevant ionic species show absorption maxima at different wavelengths. The use 
of Raman spectra and nuclear magnetic constants are also known to be used for 
a number of acids, which are regarded as strong in aqueous solution(7). 
Potentiometry is mostly used for the determination of dissociation 
constants of acids because it is economical in time. Further, it can be used for 
acids of pKa range from 2 to 11 units(6). For this measurement, glass and calomel 
electrodes have been used and carbonate free potassium hydroxide is the best 
alkali to use as a titrant. 
The potential generated by the hydrogen ions, in the solution of an acid in 
a  given  medium  is  measured  by  an  electronic  potentiometer  assembly.  The 
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relationship between the potential of glass electrode and the pH of the solution 
has the general form: 
 
0log[ ]   at 25
0.0591
cE EH pH C+ −− = = ?  
 
where E0 is the observed potential and Ec is the potential of the calomel 
electrode. The various terms in above equation change with time. So, this 
electrode cannot be used as a primary standard. However, it does provide a very 
convenient way of comparing the pH of a series of solutions. So, it is calibrated 
before and after use with a pair of known buffers, the pH of one of which must lie 
near to the pH region to be measured. The correctness of the results depends 
upon the exactness of the calibration of pH-meter. The reference solutions of 
known pH are preferred due to three primary reasons(8): 
1. Saturated calomel reference electrodes are not  highly reproducible and  this is 
     particularly true of the small immersion type electrode. 
2. The   potentials of    the commercial   glass   electrodes  vary  widely  and   the 
     symmetry potentials may fluctuate from day to day. 
3. The pH meter is usually calibrated to read directly in pH units. 
For very low pKa values, this method does not give accurate results. In 
such cases, more sensitive instruments should be used. 
The activity of the hydrogen ions is measured directly by pH metry. So, 
one can get reliable values of dissociation constant by this method. However, 
there are certain difficulties in mixed aqueous media and nonaqueous media. 
There are many applications of dissociation constants. The nature of the 
functional groups can be determined by simple comparison of acidity or 
dissociation constant of the unknown compound with those of known compounds. 
The dissociation or formation constant also provide useful informations about 
structure, tautomeric equilibria, solvent-solute interactions etc.(9). 
For water-insoluble compounds, the formation constant and other 
thermodynamic properties are measured in purely non-aqueous organic solvent 
or in a mixture of two solvents, one of which may be water. A solvent mixture 
containing water and water-miscible organic solvent is known as mixed aqueous 
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medium. A number of work has been done in non-aqueous and mixed-aqueous 
media(10-15). 
A literature survey shows that various workers studied the dissociation 
constant of a number of substances(16-22). Grunwald(23) measured ionization of 
formic, acetic and benzoic acids by differntial potentiometry. Marshall and 
Grunwald(24) measured thermodynamic parameters for the ionization reactions of 
acetic and chloroacetic acids in aqueous ethanol. The ionization constants of 
various other acids in pure and mixed solvents have also been studied(25-31). 
Feng and Waki(32) determined formation constant of some compounds by 
spectrophotometry. Allen et al. determined the acid dissociation constants of 
ionizable drugs by using multiwavelength spectrophotometer(33). 
Spectrophotometric determination of the dissociation constants of methyl yellow 
in mixed protic solvents have also been reported(34). Urquiza and Beltran(35) 
determined the dissociation constants of sulfonated azo dyes by capillary zone 
electrophoresis and spectrophotometry methods. Lachenwitzer(36) have been 
reported dissociation constant for bisulphate by using subtractively normalized 
interfacial Fourier transform infrared spectroscopy. Evagelou et al.(37) determined 
the dissociation constants of the cephalosporins, cefepime and cefpirome by 
using UV spectrometry and pH potentiometry. Kadar et al.(38) have been reported 
the spectrophotometric determination of dissociation constants of crown ethers.    
The effect of solvent on formation constant was studied by Fedorov et 
al.(39). Rengaraj et al.(40) determined the formation constant of some Schiff bases 
and their metal complexes. The proton-ligand dissociation constant of 
mercaptotriazoles was studied by Saraswathi et al.(41). The dissociation constants 
of some novel polydentate ligands have also been reported(42). Potentiometric 
studies on some binary and ternary complexes of copper containing dipicolinic 
acids and amino acids have also been reported(43).  
Determination of dissociation constants of cytokinins(44), phosphinate 
group in phosphinic pseudopeptides(45), labile drug(46), pharmaceutical active 
xanthones(47), 21 amino acids(48) etc. have been reported by using capillary zone 
electrophoresis. Some work have been reported in Schiff bases(49-52). 
 In the present work, the dissociation constant of some Schiff bases are 




         The chemicals used were of B.D.H Analar grade. All solutions used for the 
titration are prepared using distilled water. Following are the concentrations of the 
solutions used for the titration. 
Solutions     Concentration (M) 
Nitric acid     1.0 
Sodium hydroxide     0.5 
Sodium nitrate    1.0 
Schiff base (in DMF)               0.1 
 Nitric acid and sodium hydroxide were standardized by titrating with 0.1 N 
NaOH and 0.05 M succinic acid solution respectively. 
         The DMF used was of S. Merck and was purified by the reported method 
(53).    
        The buffer solutions used for the calibration of pH meter were 0.05 M 
potassium hydrogen phthalate and 0.01 M Borax buffer. 
          A systronic pH meter (Model No. EQ 664) was used for the pH 
determination. The systronic glass electrode and a saturated calomel electrode 
were used as indicator and reference electrodes respectively. Before operation, 
the glass electrode was immersed in 0.1 M HCl for twenty minutes.  Then, it was 
washed thoroughly with distilled water. 
         Before measurement, the pH meter was calibrated with buffer solution of 








Calvin Bjerrum pH titration : 
               The following sets of mixtures were prepared for titration: 
(I)   2 ml HNO3 (1.0M) + 4 ml water + 30 ml DMF + 4.0 ml NaNO3 (1.0 M).  
(ii)   2 ml HNO3 (0.1M) + 4 ml water + 28 ml DMF + 2.0 ml ligand solution 
(0.1M) + 4.0 ml NaNO3 (1.0 M).   
  Thus, total volumes (V0) in each set = 40.0 ml and DMF: water ratio  60:40 
(v/v). 
             The above mentioned solutions were allowed to attain a constant 
temperature (308.15 K) and then titrated against standard NaOH solution (0.5 M) 
under an inert atmosphere of nitrogen.  The change in the pH of solution with 













In the present work Schiff bases are of HL type. Thus, the equilibria are, 
L H HL+ ↔  
In general, these equations can be represented as: 
1j jLH H LH− + ↔  
The thermodynamic proton-ligand stability constant ( HjTK ) is given by: 




  =   
                                ... (6.1) 
TKjH is reciprocal of the thermodynamic dissociation constant of the acid LHj 
dissociating as: 
    1i iLH LH H−= +  







β   =                                      ... (6.2) 
and it refers to the reaction: 
jL JH LH+ ↔  
The stoichiometric proton-ligand stability constant is given by: 




  =   







β   =                                    ... (6.4) 
          An inert electrolyte is used to determine the stability constant in a 
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particular salt medium. Sodium nitrate is mostly preferred as supporting 
electrolyte, because of very slight complexing tendency of nitrate ion. Generally, 
the competition between nitrate ion and the ligand under study is minor 
importance. The molar concentrations are used in place of activities. 
         For the determination of dissociation constants, Bjerrum(54) introduced a 
relation for the determination of Hn , which is defined as average number of 
hydrogen bound to each ligand. 
Hn  = {K1H [H] + 2K1H K2H [H]2 + .....JK1H K2H [H] ... KjH [H]j} / {1 + K1H [H] + K1H            
K2H [H]2.....K1HK2H.....KjH [H]j                                                        ... (6.5) 
 
From equation (6.4), we can write 
























      :  ( )0 1Hβ =                 … (6.6) 
Equation (6.6) is called Bjerrum formation function of the system. 
         The determination of dissociation or formation constants from experimental 
data comprises the following three steps: (i) evaluation of formation curve of the 
system (ii) calculation of stoichiometric K`s of the system by direct solution of the 
formation function and (iii) conversion of stoichiometric constants into 
thermodynamic constants. 
         When the system consists of a ligand, which is a conjugated base of a 
weak acid, the pH-metric method introduced by Bjerrum has been widely used. 
This method is known as "Bjerrum-Calvin pH titration technique".  
 In this technique, by potentiometer, the concentration of H+ ions is 
measured. Thus, a large amount of data can be obtained in a short period of 
time. The Irving and Rossotti method(55) has some advantages, such as:  
(i) This method is valid for both pure water and for the mixed solvents.  
(ii) In this method, it is not necessary to convert the pH-meter reading in to 
stoichiometric hydrogen ion concentration.  
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(iii) It is not necessary to know the stoichiometric concentration of neutral salt 
added to maintain the ionic strength constant.  
Due to these advantages, this method is used in the present work. In this 
method, the pH-meter is standardized using an aqueous buffer. The pH (B) is 
measured for two solutions: (1) A mixture containing a mineral acid, a chelating 
agent and a neutral electrolyte to keep ionic strength constant and (2) A mixture 
same as above but without the chelating agent, when titrated against an alkali 
solution.  
  After each addition of standard alkali, the pH meter reading (B) is noted 
using a glass electrode-saturated calomel electrode combination. For both the 
titrations, same initial volume of the mixture and same standard alkali is used. 
The titration curves obtained in the above two titrations are designated as the 
reagent or ligand titration curve and the acid titration curve respectively.  
          The possible hydrolysis reactions are ignored because (i) fresh reagent 
solutions were used in pH titrations, (ii) titration times were of the order of one 
hour, (iii) there were no observable drifts with time in the meter readings and (iv) 
the concentrations of the mineral acid or alkali in the solutions were small.  
         Usually, a pH-meter calibrated with an aqueous buffer is used for aqueous 
solutions only. However, for the mixed aqueous media, especially aqueous 
dioxane solutions, Van Uitert and Haas(56) gave a relation between the glass 
electrode reading B in dioxane-water medium and the stoichiometric hydrogen 
ion concentration of the same in mixture of varied composition and ionic strength. 
They reported the relation: 
                            0log log log HH B f U
+ − = + +                                         ... (6.7) 
 where f is the activity coefficient of the hydrogen ions in the solvent mixture 
under consideration at the same temperature and ionic strength, and 0HU  is a  
correction  factor  at  zero ionic strength,  which depends only on the solvent 
composition and temperature. 0HU is taken as unity in aqueous media. The values 
of 0HU and f are reported in literature
(56). The meter reading in any aqueous 
dioxane solution can, therefore, be converted into hydrogen ion concentration 
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using equation (6.7), provided that correction factor for the appropriate solvent, 
salt medium, and temperature, has been determined.  
Equation (6.7) can be written as: 
                             01 log [ ] Hanti B H fU
+=                                         ... (6.8) 





+ ∴ =    
                      ... (6.9) 
Substituting for [H+] in equation (6.5) we get, 
Hn  = (K1H/f U0H)[1/antilog B] +....+ ((JK1H K2H...KJH) /(f U0H)J)[1/antilogB]J 
/(1+K1H/f U0H))[1/antilog B]+..+ ((K1HK2H...KJH)/(f U0H)J)[1/antilogB] ...(6.10) 
       0 .H Hj H jK fU pK=                                         ... (6.11) 
0 .H Hj H jfU pβ β=                                     ... (6.12) 
         The proton-ligand constant, pKjH can be obtained by the following methods: 
1.   Interpolation at half Hn  values: 
           At the following Hn  values, log K1 and log K2 can be determined: 
       ( )1 0.5log HK n=                                        …  (6.13) 
                                     ( )2 1.5log HK n=                                     ... (6.14) 
2.    Mid point slope method: 
 For H2L type ligands: 
                                            21 2[ ] 1K K L =  
            or                            1 2 1log 2K K pL=                                    ... (6.15) 
From the measured mid-point slope, D, the ratio K1/K2 can be calculated 








−=   +     
                                      ...  (6.16) 
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          The individual values of K1 and K2 were obtained by using K1/K2 values 

















































RESULT AND DISCUSSION 
 
 
 The titration curves obtained in the above two titrations are usually 
referred as the acid titration curve and ligand or reagent titration curve 
respectively. The titration curves for NVK-1 and NVK-10 schiff bases are shown 
in Fig. 6.1. 
 From these curves, the average number of protons associated with ligand 
(nH) can be calculated by Irring and Rossotti equation. 
( )( ){ } ( ){ }0 0 0 0'' ' 'H Ln Y V V N E V V T= − − + +        … (6.17) 
where Y is the number of displaceable protons per ligand molecule. For all the 
schiff bases, Y is taken as one. V’ and V” are the volume of alkali required at the 
same pH for both acid and ligand titration curves respectively. V0 is the initial 
volume of the test solution. N0, E0 and 0LT  are the initial concentration of the 
alkali, acid and ligand respectively. 
 The values of Hn  for all the schiff bases are given in Table 6.1. The 
general plots for the variation of Hn  with B are given in Fig. 6.2 for some schiff 
bases.  
 It is evident from Table 6.1 and Fig. 6.2 that Hn  values are in between 
zero and one. The 1
HpK  values at Hn = 0.5 were evaluated for each schiff base 
and is given in Table 6.1. 
 The plots of ( )log 1H Hn n −   against B is a straight line and are shown in 
Fig. 6.3. From these plots, 1log
HpK  values were calculated at several B by the 
following equation. 
( )1log log 1H H HpK B n n = + −          … (6.18) 
 The average 1
HpK  value is given in Table 6.1. It is evident from table that 
these 1
HpK  values are in agreement with that obtained by the Fig. 6.2 at         
Hn = 0.5. 
 Comparison of 1
HpK  values of all the schiff bases shows that, NVK-2 is 
more acidic whereas NVK-3 and NVK-8 are more basic than other studied schiff 
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bases. Both NVK-2 and NVK-3 contain methyl group. In NVK-2, it is at ortho 
position whereas in NVK-3 it is at para position. Thus, the presence of -CH3 
group at ortho position is found to increase the acidic character whereas the 
same group at para position decreases the acidity. Further, the presence of –
OCH3 and –OH groups increases the acidity as observed in NVK-1 and NVK-10 
respectively. There are two –Cl groups at meta and para positions in NVK-9 
which also shows high acidic character. However, when only one –Cl group is 
present as in NVK-6 at para position or at meta position along with fluorine group 
at para position as in NVK-4, the acidic character is decreased. The presence of 





































Figure 6.1: The plot of pH (B) against volume of NaOH (V) for NVK-1 and  
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Figure 6.2: The plot of nH against B for NVK-1, NVK-2 NVK-3 and NVK-4 at   


































Figure 6.3: The Plot of log nH/(1-nH) against B for NVK-1 and NVK-3 at   










































Table 6.1: The pH(B), nH, log pK1Hand other terms for NVK schiff bases at  
                  308.15K.  
 
B V’ V’’ V’’-V’ nH  log nH/(1-nH)   log pK1H  
NVK-1 
10.5 3.77 3.85 0.08 0.7989 3.9739 11.0992 
10.6 3.8 3.9 0.1 0.7489 2.9818 11.0745 
10.7 3.82 3.95 0.13 0.6737 2.0643 11.0148 
10.8 3.82 3.97 0.15 0.6235 1.6558 11.0190 
10.9 3.85 4 0.15 0.6237 1.6576 11.1195 
11 3.9 4.07 0.17 0.5740 1.3476 11.1296 
11.1 3.92 4.12 0.2 0.4991 0.9964 11.0984 
11.2 3.95 4.17 0.22 0.4494 0.8161 11.1118 
11.3 3.99 4.22 0.23 0.4249 0.7387 11.1685 
11.4 4.02 4.29 0.27 0.3253 0.4822 11.0832 
11.5 4.05 4.33 0.28 0.3008 0.4302 11.1337 
Half-integral value= log pK1H= (B) nH(0.5)=  11.10               Ave. log pK1H= 11.09
 
 
B V’ V’’ V’’-V’ nH  log nH/(1-nH)   log pK1H  
NVK-2 
10.5 4 4.22 0.22 0.4500 -0.0872 10.4128 
10.6 4.02 4.27 0.25 0.3753 -0.2213 10.3787 
10.7 4.05 4.3 0.25 0.3757 -0.2205 10.4795 
10.8 4.07 4.35 0.28 0.3011 -0.3657 10.4343 
10.9 4.1 4.37 0.27 0.3265 -0.3144 10.5856 
11 4.12 4.4 0.28 0.3019 -0.3640 10.6360 
11.1 4.15 4.43 0.28 0.3024 -0.3631 10.7369 
11.2 4.2 4.47 0.27 0.3281 -0.3114 10.8886 
11.3 4.24 4.52 0.28 0.3038 -0.3602 10.9398 
11.4 4.28 4.57 0.29 0.2796 -0.4111 10.9889 
11.5 4.3 4.6 0.3 0.2551 -0.4654 11.0346 
11.6 4.34 4.63 0.29 0.2806 -0.4090 11.1910 
11.7 4.38 4.67 0.29 0.2812 -0.4076 11.2924 
11.8 4.45 4.7 0.25 0.3813 -0.2102 11.5898 
11.9 4.47 4.75 0.28 0.3074 -0.3528 11.5472 
12 4.55 4.8 0.25 0.3827 -0.2076 11.7924 
Half- integral value= log pK1H= (B) nH(0.5)= 11.00               Ave. log pK1H= 10.93











B V’ V’’ V’’-V’ nH  log nH/(1-nH)   log pK1H  
NVK-3 
10.8 4.2 4.3 0.1 0.2489 0.4797 11.2797 
10.9 4.22 4.35 0.13 0.3234 0.3206 11.2206 
11 4.25 4.37 0.12 0.2983 0.3715 11.3715 
11.1 4.27 4.4 0.13 0.3230 0.3214 11.4214 
11.2 4.3 4.45 0.15 0.3725 0.2266 11.4266 
11.3 4.32 4.5 0.18 0.4468 0.0929 11.3929 
11.4 4.35 4.55 0.2 0.4961 0.0069 11.4069 
11.5 4.37 4.59 0.22 0.5454 -0.0791 11.4209 
11.6 4.4 4.66 0.26 0.6441 -0.2577 11.3423 
11.7 4.42 4.69 0.27 0.6686 -0.3048 11.3952 
11.8 4.44 4.74 0.3 0.7426 -0.4601 11.3399 
11.9 4.47 4.77 0.3 0.7421 -0.4590 11.4410 
Half- integral value= log pK1H= (B) nH(0.5)= 11.40               Ave. log pK1H= 11.37
 
 
B V’ V’’ V’’-V’ nH log nH/(1-nH) log pK1H 
NVK-4 
10.7 4.25 4.4 0.15 0.6271 0.2258 10.9258 
10.8 4.27 4.45 0.18 0.5527 0.0920 10.8920 
10.9 4.3 4.48 0.18 0.5530 0.0925 10.9925 
11 4.31 4.5 0.19 0.5283 0.0493 11.0493 
11.1 4.35 4.52 0.17 0.5784 0.1372 11.2372 
11.2 4.35 4.55 0.2 0.5039 0.0069 11.2069 
11.3 4.37 4.6 0.23 0.4298 -0.1228 11.1772 
11.4 4.4 4.65 0.25 0.3806 -0.2114 11.1886 
11.5 4.42 4.68 0.26 0.3561 -0.2572 11.2428 
11.6 4.45 4.72 0.27 0.3318 -0.3040 11.2960 
11.7 4.47 4.75 0.28 0.3074 -0.3528 11.3472 
11.8 4.5 4.78 0.28 0.3079 -0.3518 11.4482 
Half- integral value= log pK1H= (B) nH(0.5)= 11.08               Ave. log pK1H= 11.17
















B V’ V’’ V’’-V’ nH  log nH/(1-nH)   log pK1H  
NVK-5 
10.5 4.07 4.12 0.05 0.8752 0.8459 11.3459 
10.6 4.1 4.17 0.07 0.8254 0.6746 11.2746 
10.7 4.12 4.22 0.1 0.7507 0.4787 11.1787 
10.8 4.15 4.25 0.1 0.7508 0.4791 11.2791 
10.9 4.17 4.27 0.1 0.7510 0.4794 11.3794 
11.0 4.2 4.32 0.12 0.7014 0.3708 11.3708 
11.1 4.25 4.37 0.12 0.7017 0.3715 11.4715 
11.2 4.27 4.47 0.2 0.5030 0.0053 11.2053 
11.3 4.3 4.52 0.22 0.4537 -0.0806 11.2194 
11.4 4.32 4.57 0.25 0.3795 -0.2135 11.1865 
11.5 4.32 4.6 0.28 0.3051 -0.3576 11.1424 
Half- integral value= log pK1H= (B) nH(0.5)= 11.20               Ave. log pK1H= 11.28
 
 
B V’ V’’ V’’-V’ nH  log nH/(1-nH)   log pK1H  
NVK-6 
10.5 3.82 3.87 0.05 0.8745 0.8431 11.3431 
10.6 3.85 3.92 0.07 0.8244 0.6716 11.2716 
10.7 3.9 3.97 0.07 0.8246 0.6722 11.3722 
10.8 3.95 4.05 0.1 0.7497 0.4765 11.2765 
10.9 3.97 4.1 0.13 0.6748 0.3170 11.2170 
11.0 4.02 4.15 0.13 0.6751 0.3177 11.3177 
11.1 4.07 4.22 0.15 0.6256 0.2230 11.3230 
11.2 4.1 4.27 0.17 0.5760 0.1330 11.3330 
11.3 4.15 4.35 0.2 0.5017 0.0030 11.3030 
11.4 4.17 4.43 0.26 0.3525 -0.2641 11.1359 
11.5 4.2 4.47 0.27 0.3281 -0.3114 11.1886 
11.6 4.25 4.55 0.3 0.2542 -0.4674 11.1326 
Half- integral value= log pK1H= (B) nH(0.5)= 11.30               Ave. log pK1H= 11.27

















B V’ V’’ V’’-V’ nH  log nH/(1-nH)   log pK1H  
NVK-7 
10.5 3.9 4 0.1 0.7494 0.4758 10.9758 
10.6 3.92 4.02 0.1 0.7495 0.4761 11.0761 
10.7 3.97 4.07 0.1 0.7498 0.4767 11.1767 
10.8 4 4.1 0.1 0.7500 0.4771 11.2771 
10.9 4.03 4.15 0.12 0.7002 0.3684 11.2684 
11.0 4.07 4.2 0.13 0.6755 0.3184 11.3184 
11.1 4.1 4.27 0.17 0.5760 0.1330 11.2330 
11.2 4.15 4.35 0.2 0.5017 0.0030 11.2030 
11.3 4.2 4.42 0.22 0.4525 -0.0828 11.2172 
11.4 4.22 4.45 0.23 0.4279 -0.1262 11.2738 
11.5 4.27 4.52 0.25 0.3788 -0.2148 11.2852 
11.6 4.32 4.6 0.28 0.3051 -0.3576 11.2424 
11.7 4.37 4.65 0.28 0.3058 -0.3560 11.3440 
Half- integral value= log pK1H= (B) nH(0.5)= 11.26              Ave. log pK1H= 11.22 
 
 
B V’ V’’ V’’-V’ nH  log nH/(1-nH)   log pK1H  
NVK-8 
10.7 3.8 3.85 0.05 0.8744 0.8428 11.5428 
10.8 3.82 3.88 0.06 0.8494 0.7512 11.5512 
10.9 3.85 3.92 0.07 0.8244 0.6716 11.5716 
11 3.87 3.95 0.08 0.7994 0.6005 11.6005 
11.1 3.9 4.02 0.12 0.6993 0.3666 11.4666 
11.2 3.93 4.07 0.14 0.6494 0.2678 11.4678 
11.3 3.95 4.15 0.2 0.4994 -0.0010 11.2990 
11.4 3.97 4.22 0.25 0.3746 -0.2226 11.1774 
11.5 4 4.27 0.27 0.3250 -0.3174 11.1826 
11.6 4.05 4.35 0.3 0.2509 -0.4752 11.1248 
Half- integral value= log pK1H= (B) nH(0.5)= 11.30              Ave. log pK1H= 11.40 

















B V’ V’’ V’’-V’ nH  log nH/(1-nH)   log pK1H  
NVK-9 
10.5 4.1 4.17 0.07 0.8254 0.6746 11.1746 
10.6 4.12 4.2 0.08 0.8005 0.6035 11.2035 
10.7 4.15 4.25 0.1 0.7508 0.4791 11.1791 
10.8 4.17 4.3 0.13 0.6763 0.3199 11.1199 
10.9 4.2 4.35 0.15 0.6267 0.2250 11.1250 
11.0 4.22 4.4 0.18 0.5522 0.0911 11.0911 
11.1 4.25 4.45 0.2 0.5028 0.0049 11.1049 
11.2 4.3 4.52 0.22 0.4537 -0.0806 11.1194 
11.3 4.32 4.57 0.25 0.3795 -0.2135 11.0865 
11.4 4.35 4.62 0.27 0.3303 -0.3069 11.0931 
11.5 4.37 4.65 0.28 0.3058 -0.3560 11.1440 
Half-integral value= log pK1H= (B) nH(0.5)= 11.12                Ave. log pK1H= 11.13
 
 
B V’ V’’ V’’-V’ nH  log nH/(1-nH)   log pK1H  
NVK-10 
10.6 3.87 3.95 0.08 0.7994 0.6005 11.2005 
10.7 3.9 3.99 0.09 0.7745 0.5358 11.2358 
10.8 3.92 4.05 0.13 0.6744 0.3162 11.1162 
10.9 3.95 4.1 0.15 0.6246 0.2211 11.1211 
11.0 3.97 4.12 0.15 0.6247 0.2214 11.2214 
11.1 4 4.2 0.2 0.5000 0.0000 11.1000 
11.2 4.05 4.27 0.22 0.4506 -0.0861 11.1139 
11.3 4.07 4.35 0.28 0.3011 -0.3657 10.9343 
11.4 4.1 4.37 0.27 0.3265 -0.3144 11.0856 
11.5 4.12 4.42 0.3 0.2520 -0.4724 11.0276 
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 Biological activity spectrum of a compound represents the 
pharmacological effects, physiological and biochemical mechanisms of action, 
specific toxicity which can be revealed in compounds interaction with biological 
system. Further, it describes the intrinsic properties of the compound which 
depends on its structure. 
 A literature survey shows that quinoline derivatives possess various 
biological activities(1-5). Further, the schiff bases have been reported to 
demonstrate a wide rage of pharmacological activities(6-10), which include 
antibacterial(11-12), antitumor(13), anti-inflammatory(14), antifungal(15), anti-HIV(16), 
antipyretic (17,18)etc. 
 With a variety of biological activity, chalcones are useful in 
pharmaceuticals. They are associated with biological activities like anti-
inflammatory(19), antiulcer(20), fungicidal(21), antiviral(22), antitumor(23), 
anticancer(24), bactrericidal(25), insecticidal(26), antimalarial(27) etc., while 
pyrazolines are also reported to possess various biological activities like 
tranquilizing(28), anticonvulsant(29), herbicidal(30), antifungal(31), insecticidal(32), anti-
inflammatory(33), antibacterial(34), antidiabetic(35), antidepresent(36) etc. Pyrimidine 
derivatives possess different biological activities such as antiviral(37), 
anticarcinogencic activity(38), antiinflammaroty(39), analgesic(40), 
antihypertensive(41), blood platelet      aggregation inhibitory activity(42), anti-HIV(43) 
and antibacterial activity(44) etc. 
 Much research has been carried out with the aim to finding therapeutic 
values of pyrazole moiety. A large number of substituted pyrazole derivatives are 
prepared and tested for variety of biological activities like anthelmintic(45), CNS 
depressant(46), lipoxygenase inhibitor(47), antimicrobial(48), antioxidant(49), 
cardiovascular agent(50) and antiHIV(51) etc. Various imidazolinones are also 
known to exhibit a broad spectrum of biological activities such as 
antiparkinsonian(52), hypertensive(53), potent CNS depressant(54), antiviral(55), 
anticonvulsant(56),  inflammatory(57,58), bactericidal(59), antitubercular(60), 
antimicrobial(61), anti- insecticidal(62), fungicidal(63) etc. 
In this chapter, antibacterial activity of all the synthesized compounds has 




 The antibacterial activities of all the synthesized compounds, i.e., Schiff 
bases, Chalcones, imidazolinone derivatives, pyrazolines, thiopyrimidine etc. 
were studied in DMSO. 
 DMSO is a versatile non-aqueous dipolar aprotic solvent having a 
dielectric constant of 46.6 (25oC) and a dipole moment of 3.9 D (25oC).  It is a 
highly polar but aprotic solvent, which can mix well with any liquid.  It is also 
called a super solvent and exhibits quite interesting properties. 
 All the synthesized compounds were recrystallized prior to use. The 
solvent DMSO was also purified before use by standard method(64). 
 Two methods were adopted for the study: Agar disc diffusion method and 
Agar well diffusion method.  
 In Agar disc diffusion method, the concentration of compounds were less 
than that used in Agar well diffusion method. 
 For Schiff bases, chalcones and imidazolinone derivatives, Agar disc 
diffusion method was used.  
 
Agar disc diffusion method(65): 
The antibacterial assay was evaluated by the method of agar disc diffusion 
method. The media used for the antibacterial assay were Mueller Hinton Agar 
No.2 and SDA media. The test strain (200 µl) was inoculated into the media 
(inoculums size 108cells/ml) when the temperature reached 40-42 °C and poured 
into Petri dishes (Hi-Medial). 20 µl of the test compound was impregnated in to 
sterile discs (7 mm, Hi-Media), allowed to dry and was introduced on the upper 
layer of the seeded agar plate. The plates were incubated overnight at 37 °C. The 
experiment was performed under strict aseptic conditions. Microbial growth was 
determined by measuring the diameter of zone of inhibition. For each bacterial 
strain controls were maintained where pure solvent was used instead of the 
extract.  The result was obtained by measuring the zone diameter. The 
experiment was done three times and the mean values are presented.  
Preparation of test compounds: 
  For all the compounds, the solutions were prepared in DMSO. 





 The bacterial strains studied are identified strains and were obtained from 
National Chemical Laboratory (NCL), Pune, INDIA. The investigated micro 
organisms are Proteus mirabilis NCIM2241 (PM), Staphylococcus aureus 
ATCC25923 (SA), Bacillus cereus ATCC11778 (BC), E. coli ATCC25922 (EC), 
Candida tropicalis ATCC4563 (CT), Candida albicans ATCC2091 (CA). 
 
 For pyrazoline and thiopyrimidine derivatives, Agar well diffusion method 
was used. 
 
Agar well diffusion method(66,67):  
The antibacterial evaluation was done by agar well diffusion method using 
Mueller Hinton Agar No.2 as the nutrient medium.  The agar well diffusion 
method was preferred to be used in this study since it was found to be better than 
the disc diffusion method as suggested by(67). The bacterial strains were activated 
by inoculating a loop full of test strain in 25ml of N-broth and the same was 
incubated for 24h in an incubator at 37o C. 0.2 ml of the activated strain was 
inoculated in Mueller Hinton Agar. Mueller Hinton Agar kept at 45oC was then 
poured in the Petri dishes and allowed to solidify. After solidification of the media, 
0.85 cm well was made in the plates using a sterile cork borer. Each well was 
filled with 0.1 ml of the test solution.  The plates were incubated for 24 h at 37oC.  
The mean value obtained for the three wells was used to calculate the zone of 
growth inhibition of each sample. The controls were maintained for each bacterial 
strain, where pure solvent (DMSO) was inoculated into the well. The inhibition 
zone formed by these compounds against the particular test bacterial strain 
determined the antibacterial activities of the synthetic compounds.  
Preparation of the test compound 
The synthesized test compounds were dissolved in DMSO at a 
concentration of 20 mg/ml.  
Test microorganisms 
The synthesized compounds were tested for its antibacterial activity 
against four Gram positive Bacillus cereus ATCC11778, Staphylococcus aureus 
ATCC29737, Staphylococcus epidermidids NCIM2493 and Micrococcus luteus 
ATCC10240, and three Gram negative bacteria viz. Proteus mirabilis NCIM2241, 
Escherichia coli ATCC25922 and Klebsiella aerogenes NICM2098 bacteria.  
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Microorganisms were obtained from National Chemical Laboratory (NCL), Pune, 


































RESULTS AND DISCUSSION 
 
Table 1: Activity of Schiff bases, Chalcones and Imidazolinone derivatives. 
 
Comp.  
Code PM SA BC EC CT CA 
NVK-1A + + + - - - 
NVK-1B + + - - - - 
NVK-1C - - - - - - 
NVK-1D - - - + - - 
NVK-1E - - - + - - 
NVK-1F + - - - + - 
NVK-1G - - - - + - 
NVK-1H - - - + - - 
NVK-1I - - - - - - 
NVK-1J - - - - - - 
NVK-2A - - - - - - 
NVK-2B - - - - + - 
NVK-2C - - - - ++ - 
NVK-2D - - - - - - 
NVK-2E - + - - - - 
NVK-2F - - - - - - 
NVK-2G - + - - - - 
NVK-2H - - - - + - 
NVK-2I - - - - + + 
NVK-2J - + + - - - 
PAIM-1 - + - - - - 
PAIM-2 - - - - - - 
PAIM-3 - - - - - - 
PAIM-4 - - + - - + 
PAIM-5 + + + - - + 
PAIM-6 - - - - - - 
PAIM-7 - - - - - - 
PAIM-8 - - - - - - 
PAIM-9 -  - - - - 
G +++ ++ ++ + - - 
Pc +++ +++ ++ ++ - - 
Ns - - - - - + 
Fu - - - - ++ ++ 
 
(+) = 9-14mm (zone diameter)  
(++) = 15-20mm (zone diameter) 
(++) = 21-30mm (zone diameter) 




 Table 1 shows the activity of schiff bases, chalcones and imidazolinone 
derivatives against different bacterial strains. 
 For comparison the antibacterial activity of Gentamicin (G), Piperacillin 
(Pc), Fluconazole (Fu) and Nystatin (Ns) were also reported. 
 It is evident from the Table 1 that most of these compounds do not exhibit 
activity against the studied bacteria. However, No.13 shows some significant 
activity against Candida tropicalis ATCC4563 (CT) as exhibited by drug 
Fluconazole (Fu). 
 The antibacterial activity of pyrazolines and thiopyrimidine derivatives 
which was studied by agar well diffusion method, are shown in Fig. 1-4. As it is 
evident from these figures that, these compounds are quite active against the 




The antibacterial activity of NVK(3A-3J) pyrazolines against Gram positive 
bacteria are shown in Fig. 1 while that of NVK (3A-3J) pyrazolines against Gram 
negative bacteria are shown in Fig. 2.  B. cereus was the most susceptible Gram 
positive bacteria while M. luteus was the most resistant Gram negative bacterial 
strain.  All the 10 pyrazolines showed activity against B. cereus but to a varied 
level.  Maximum activity was shown by compound NVK-3E, followed by 
compound NVK-3G and NVK-3J.  Minimum activity was shown by compound 
NVK-3H and NVK-3I. When S. aureus, the most resistant Gram positive bacteria 
was considered, all the ten compounds showed almost similar activity.  Only 
compound NVK-3E, NVK-3F, NVK-3G and NVK-3J showed antibacterial activity 
against M. luteus; compound NVK-3E showed maximum activity.  Compound 
NVK-3G showed maximum activity against S. epidermidis while compound NVK-
3F and NVK-3I showed the least activity.  
When Gram negative bacterial strains are considered, E. coli was the most 
resistant strain while K. aerogenes was the most susceptible strain. Compound 
NVK-3I did not show activity against P. mirabilis while compound NVK-3H did not 
show activity against K. aerogenes.  Maximum activity was shown by compound 
NVK-3E against K. aerogenes followed by NVK-3A and NVK-3D; while all the 
compounds showed almost similar activity against P. mirabilis.  
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The obtained results showed different levels of activities against both 
Gram positive and Gram negative bacteria.  Gram positive bacteria were found to 
be more susceptible than Gram negative bacteria.  This could be due to the fact 
that the cell wall of Gram positive bacteria is less complex and lack the natural 
sieve effect against large molecules due to the small pores in their cell 
envelope(73). Gram negative bacteria which are responsible for a large number of 
infectious diseases have a unique outer membrane that contains lipo 
polysaccharides which render them impermeable to certain antibacterial 
compounds(74). 
Amongst the ten pyrazoline derivatives synthesized, only R is different in 
all the 10 compounds. It is observed that compound NVK-3E which has nitro 
group at para position shows the best activity. This is followed by compound 
NVK-3G and NVK-3J which has para methyl and para bromo groups 
respectively. 
This differential activity of the compounds is because of the structural 
differences.  The presence of nitro group enhances the activity. However, the 
methyl and bromide group attached at para position also increases the activity. 
The presence of nitro group at meta position decreases the activity which may be 
due to some steric hindrance. Other substituents are not very effective in 
inhibition. 
A rapid and effective response to challenge pathogens is essential for the 
survival of all living organisms. The need for efficient agents increases with the 
expanding number of immunodeficient patients and with the emergence of 
bacterial and fungal pathogens resistant to current therapies(75). 
From the above results it can be concluded that the pyrazoline derivatives 
which had nitro group showed best antibacterial activity provided the nitro group 
was at para position while the same nitro group at meta position decreased the 
activity. The next best was pyrazoline derivatives with methyl and bromo group at 
para position. Lastly, these compounds showed better antibacterial activity 





 The antibacterial activity of NVK(4A-4K) pyrazolines against Gram positive 
bacteria are shown in Fig. 3 while that of NVK (4A-4K) pyrazolines against Gram 
negative bacteria are shown in Fig. 4. 
All the 11 thiopyrimidines synthesized showed different activity against 
different bacterial strains.  This may be because all the 11 compounds have 
different structures.  Our earlier findings(76,77) suggest that there is a direct 
correlation between structure and antibacterial activity.     
  M. luteus was the most resistant Gram positive bacteria followed by S. 
epidermidis. Only 4 compounds NVK (4A-4D) showed activity against M. luteus 
while all others were inactive.  Compound NVK-4B had nitro group at meta 
position and compound NVK-4E had same nitro group but at para position; this 
small structural difference resulted in inactivity.  A similar effect was observed 
between compound NVK-4D and NVK-4F.   
Only 5 compounds (NVK-4A, NVK-4B, NVK-4D, NVK-4E and NVK-4F) 
showed activity against S. epidermidis. The maximum activity was shown by 
compound NVK-4F which had amino group at meta position.  On the other hand, 
8 compounds showed activity against B. cereus; only compounds (NVK-4I – 
NVK-4K) were ineffective against this bacterial strain. Maximum activity was 
shown by compound NVK-4A.  Only 7 compounds showed activity against S. 
aureus (Fig. 3). In this case also, maximum activity was shown by NVK-4A. 
The potential of the synthesized thiopyrimidine derivatives against Gram 
negative bacteria are shown in Fig. 4.  E. coli was the most resistant strain only 
compound NVK-4J showed some activity.  The thiopyrimidine derivatives showed 
more activity towards K. aerogenes as compared to P. mirabilis.  Maximum 
antibacterial activity was shown by compound NVK-4A against both these Gram 
negative strains.  
The differential activity of the compounds against different bacterial strains 
is because of the differences in their structures.  All the compounds have 
common central moiety. The compound NVK-4A, which showed maximum 
activity, consisted of p-methoxy benzyldehyde; while the least activity was shown 
by Compound NVK-4I, NVK-4J and NVK-4K.  The R groups in these three 
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compounds were 4-Cl, 4-Br and 2-methyl which decreased the antibacterial 
activity. 
From the above results, it can be concluded that thiopyrimidine derivative 
which had p-methoxy benzyldehyde showed best antibacterial activity. All the 
other groups in fact decreased the activity. All the eleven compounds showed 
better antibacterial activity towards Gram positive bacteria than Gram negative 
bacteria. The results also suggest that there is no universal criteria regarding the 
group attached, the position where it is present,  in concluding whether it is a 
good antibacterial agent or not.  The same compound may show good 
antibacterial activity towards one strain while it may inhibit another strain.  It can 
only conclude that in a particular set of compounds, which structural formula is 
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